## metadata
source file: data/floodlamp/reg/fda-townhalls/f5_fixnames/run_auto/2023-03-22_Virtual Town Hall 102_fixnames.md
last updated: 2025-01-05 Created QA Sections
link pdf: https://www.fda.gov/media/166605/download?attachment
link youtube: https://youtu.be/DsKd5harDO4
link slides: https://www.fda.gov/media/166606/download?attachment
topic: COVID-19 and Monkeypox


## content

### qa


#### 1. Final Virtual Town Hall on Mpox and COVID-19 Testing

QA Block 1-1
CLARIFIED QUESTION: What are the next steps for transitioning from EUA tests to fully authorized tests under traditional marketing submissions?
CLARIFIED ANSWER: FDA encourages developers to submit a Q-Sub or Pre-Sub for transitioning from EUA tests to full authorization. EUA data can generally be used to reduce validation efforts, and FDA can provide standard validation recommendations upon request.
VERBATIM QUESTION: What are the next steps for transitioning from EUA tests to fully authorized tests under traditional marketing submissions?
VERBATIM ANSWER: As we have discussed on previous town halls, we are encouraging stakeholders to move towards a traditional marketing submission. Developers are encouraged to submit a Q-Sub or a Pre-Sub to address questions they have for these conversions from EUA tests to fully authorize tests. We will, in general, allow use of the EUA data to decrease the validation needed. And this can be worked out through the Q-Sub, Pre-Sub process. We can also provide, through this process, our standard validation recommendations for your device type upon request.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Transition from EUA, FDA Q-Sub/Pre-Sub process, Validation requirements
REVIEW FLAG: False

QA Block 1-2
CLARIFIED QUESTION: How can developers leverage EUA data to reduce validation requirements when transitioning to fully authorized tests?
CLARIFIED ANSWER: FDA recommends that developers use the Q-Sub or Pre-Sub process to address questions regarding the transition from EUA to full authorization, leveraging EUA data to reduce validation requirements.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: Developers are encouraged to submit a Q-Sub or a Pre-Sub to address questions they have for these conversions from EUA tests to fully authorize tests. We will, in general, allow use of the EUA data to decrease the validation needed. And this can be worked out through the Q-Sub, Pre-Sub process. We can also provide, through this process, our standard validation recommendations for your device type upon request.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA transition to full authorization, Validation requirements, Q-Sub/Pre-Sub process
REVIEW FLAG: False

QA Block 1-3
CLARIFIED QUESTION: What is the process for obtaining FDA validation recommendations for a specific device type?
CLARIFIED ANSWER: FDA recommends developers submit a Q-Sub or Pre-Sub to obtain validation recommendations for their device type, which may include using existing EUA data to reduce validation requirements.
VERBATIM QUESTION: What is the process for obtaining FDA validation recommendations for a specific device type?
VERBATIM ANSWER: Developers are encouraged to submit a Q-Sub or a Pre-Sub to address questions they have for these conversions from EUA tests to fully authorize tests. We will, in general, allow use of the EUA data to decrease the validation needed. And this can be worked out through the Q-Sub, Pre-Sub process. We can also provide, through this process, our standard validation recommendations for your device type upon request.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA validation process, EUA to full authorization, Q-Sub and Pre-Sub submissions
REVIEW FLAG: False

QA Block 1-4
CLARIFIED QUESTION: What COVID-19 and mpox EUA review priorities is the FDA focusing on at this stage?
CLARIFIED ANSWER: FDA is focusing on a very limited set of priorities for COVID-19 and mpox Emergency Use Authorization (EUA) reviews at this time.
VERBATIM QUESTION: What COVID-19 and mpox EUA review priorities is the FDA focusing on at this stage?
VERBATIM ANSWER: We are focusing on only a very limited set of priorities for both COVID-19 and mpox EUA reviews at this time.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA review priorities, COVID-19, mpox
REVIEW FLAG: False

QA Block 1-5
CLARIFIED QUESTION: When will the final guidance on the COVID-19 transition plan be released?
CLARIFIED ANSWER: The FDA plans to finalize the COVID-19 transition plan guidance soon and will host a town hall/webinar for IVD developers after its release.
VERBATIM QUESTION: When will the final guidance on the COVID-19 transition plan be released?
VERBATIM ANSWER: The COVID-19 transition plan guidance, issued in draft in December of 2021, will be finalized soon and will include additional information on the transition back to normal operations. We will host a town hall/webinar on the final guidance for IVD developers following the final guidance release, so be on the lookout for that announcement.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19 transition guidance, IVD developer resources
REVIEW FLAG: False

QA Block 1-6
CLARIFIED QUESTION: Will there be opportunities for FDA-hosted webinars focused on specific IVD topics after the end of regular town halls?
CLARIFIED ANSWER: The FDA may schedule ad hoc webinars on specific IVD topics in the future and will remain available via email for questions.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: Over the last three years, we have hosted more than 100 virtual town halls and have really enjoyed having this time to connect with all of you, learn more about your development activities and pain points, and answer your questions. While we won't be holding these sessions regularly, we will still be available for questions. You can always reach out to us by email at COVID19Dx@fda.hhs.gov, or for mpox, the MPXDx@fda.hhs.gov. Additionally, we may schedule ad hoc webinars on special topics for IVDs in the future, as this format seems to be helpful to many developers and other stakeholders.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Future FDA IVD webinars, Transition from recurring town halls, Support for stakeholders
REVIEW FLAG: False

QA Block 1-7
CLARIFIED QUESTION: How flexible is the FDA in adapting its recommendations for specific developer challenges during the transition process?
CLARIFIED ANSWER: The FDA remains flexible in adapting recommendations to specific developer challenges, encouraging discussion through pre-EUA or Q-Sub processes to address and potentially update recommendations for unique situations.
VERBATIM QUESTION: How flexible is the FDA in adapting its recommendations for specific developer challenges during the transition process?
VERBATIM ANSWER: FDA recommendations in general, that is things like recommendations made in the COVID and mpox templates, and the standards ways of evaluating both EUAs for emergency response and traditional marketing IVD submissions are just that, recommendations. They are not hard and fast requirements. Through the COVID response and into the mpox response, the FDA has displayed a high degree of flexibility to meet the needs to match the situation currently on the ground. This is very much our standard operating procedure. So if our recommendations present significant challenges, reach out to us via either a pre-EUA for emergency response submissions or Q-Subs for full submissions, and discuss it with us. Present the issue, the challenge that you face, and a suggested way to overcome it. And we will review it and let you know through those either of those formal processes. We will consider changes to our recommendation when it makes sense for a specific given situation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA flexibility, Transition process, Recommendations
REVIEW FLAG: False

QA Block 1-8
CLARIFIED QUESTION: What is the procedure for proposing modifications or alternatives to FDA recommendations through the pre-EUA or Q-Sub processes?
CLARIFIED ANSWER: FDA suggests using the pre-EUA or Q-Sub processes to discuss challenges with their recommendations and propose alternatives or modifications. Developers should present the issue, suggest solutions, and FDA will review and respond accordingly.
VERBATIM QUESTION: What is the procedure for proposing modifications or alternatives to FDA recommendations through the pre-EUA or Q-Sub processes?
VERBATIM ANSWER: FDA recommendations in general, that is things like recommendations made in the COVID and mpox templates, and the standards ways of evaluating both EUAs for emergency response and traditional marketing IVD submissions are just that, recommendations. They are not hard and fast requirements. Through the COVID response and into the mpox response, the FDA has displayed a high degree of flexibility to meet the needs to match the situation currently on the ground. This is very much our standard operating procedure. So if our recommendations present significant challenges, reach out to us via either a pre-EUA for emergency response submissions or Q-Subs for full submissions, and discuss it with us. Present the issue, the challenge that you face, and a suggested way to overcome it. And we will review it and let you know through those either of those formal processes. We will consider changes to our recommendation when it makes sense for a specific given situation. We have demonstrated that we have done this, and will continue to demonstrate it going forward.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Q-Sub process, pre-EUA process, FDA flexibility
REVIEW FLAG: False

QA Block 1-9
CLARIFIED QUESTION: What is the FDA's current position on developing and authorizing mpox screening tests?
CLARIFIED ANSWER: The FDA is open to developing mpox screening tests and recommends interested developers to submit a pre-EUA. Lesion-based testing remains the most reliable method currently, but US government studies may aid in determining sample types or screening methods.
VERBATIM QUESTION: What is the FDA's current position on developing and authorizing mpox screening tests?
VERBATIM ANSWER: We have had questions about screening tests for mpox. The FDA is open to such screening tests. And if interested, please submit a pre-EUA. There are various US government-sponsored studies that are looking at this and may help inform both the sample type and/or appropriateness of a specific screening method. For the moment, though, lesion-based testing remains the most reliable method of detecting mpox.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: mpox screening tests, FDA authorization process, lesion-based testing
REVIEW FLAG: False

QA Block 1-10
CLARIFIED QUESTION: Are US government-sponsored studies on mpox screening tests influencing FDA recommendations or approval processes?
CLARIFIED ANSWER: US government-sponsored studies on mpox screening tests may influence FDA guidance on sample types and screening methods, but lesion-based testing remains the most reliable approach for now.
VERBATIM QUESTION: Are US government-sponsored studies on mpox screening tests influencing FDA recommendations or approval processes?
VERBATIM ANSWER: There are various US government-sponsored studies that are looking at this and may help inform both the sample type and/or appropriateness of a specific screening method. For the moment, though, lesion-based testing remains the most reliable method of detecting mpox.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: mpox screening tests, FDA approvals, US government-sponsored studies
REVIEW FLAG: False


#### 2. COVID-19 Test Transition and Validation Guidelines

QA Block 2-1
CLARIFIED QUESTION: What are the appropriate COVID-19 comparator methods to support a de novo or 510k premarket submission?
CLARIFIED ANSWER: FDA recommends using an FDA-cleared RT-PCR test as the top choice for COVID-19 comparator methods to support a de novo or 510k premarket submission. For alternate comparators, submitting a Q-Sub or Pre-Sub allows FDA to provide guidance on appropriate methods.
VERBATIM QUESTION: What are the appropriate COVID-19 comparator methods to support a de novo or 510k premarket submission?
VERBATIM ANSWER: The top choice for comparator methods for COVID-19 is an FDA-cleared RT-PCR test. As there are a variety of factors to consider for alternate comparator methods, we recommend that you submit a Q- Sub or Pre-Sub, and we will provide additional information on appropriate comparators for your particular situation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: COVID-19 comparator methods, de novo submission, 510k submission
REVIEW FLAG: False

QA Block 2-2
CLARIFIED QUESTION: What comparator method do you recommend for flu when supporting a multi-analyte respiratory panel?
CLARIFIED ANSWER: The FDA recommends using a highly-sensitive, FDA-cleared RT-PCR test as the comparator method for flu in a multi-analyte respiratory panel, preferably one cleared within the past five years. Older tests may be acceptable if performance with current flu strains can be demonstrated.
VERBATIM QUESTION: What comparator method do you recommend for flu when supporting a multi-analyte respiratory panel?
VERBATIM ANSWER: To support a multi-analyte respiratory panel, we recommend that the comparative method for flu be a highly-sensitive, FDA-cleared, RT-PCR test, and typically we recommend that this is cleared within the past five years. However, we may consider a comparator that has been cleared previous to that time frame if you can demonstrate that the test performance is expected to remain unchanged with currently circulating flu strains; for example, providing an in silico analysis of the primers and probes, including contemporary strains.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: Comparator methods for flu, Multi-analyte respiratory panels, RT-PCR tests
REVIEW FLAG: False

QA Block 2-3
CLARIFIED QUESTION: Can a comparator cleared over five years ago be used if the test performance remains unchanged with currently circulating flu strains?
CLARIFIED ANSWER: FDA may accept a comparator test cleared over five years ago if you demonstrate that its performance is unchanged with current flu strains, such as through an in silico analysis of primers and probes including contemporary strains.
VERBATIM QUESTION: Can a comparator cleared over five years ago be used if the test performance remains unchanged with currently circulating flu strains?
VERBATIM ANSWER: We may consider a comparator that has been cleared previous to that time frame if you can demonstrate that the test performance is expected to remain unchanged with currently circulating flu strains; for example, providing an in silico analysis of the primers and probes, including contemporary strains.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: Comparator test clearance, Flu strain test performance
REVIEW FLAG: False

QA Block 2-6
CLARIFIED QUESTION: What information should be included in a Pre-Sub or Q-Sub regarding specific potential comparators and study design?
CLARIFIED ANSWER: FDA recommends including details about your device, validation plans, and specific questions in a Pre-Sub or Q-Sub to receive tailored feedback for comparators and study designs.
VERBATIM QUESTION: What information should be included in a Pre-Sub or Q-Sub regarding specific potential comparators and study design?
VERBATIM ANSWER: For questions related to specific submissions, including regarding special potential comparators-- sorry, excuse me, specific potential comparators and study designs, we recommend that you submit a Pre-Sub, also known as a Q-Sub, with information about your device, validation plans, and specific questions so that we can provide appropriate feedback and answers to your questions after considering your test- specific issues.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: Pre-Sub/Q-Sub information, Study design, Comparators
REVIEW FLAG: False

QA Block 2-7
CLARIFIED QUESTION: What are your recommendations for flu B validation given its low prevalence in the U.S.?
CLARIFIED ANSWER: The FDA recognizes the low prevalence of flu B and recommends targeting at least 30 flu B-positive subjects in a prospective study for CLIA waiver or OTC IVD indications, reduced from previous targets of 120. Discussions on validation plans with FDA are encouraged as recommendations may evolve.
VERBATIM QUESTION: What are your recommendations for flu B validation given its low prevalence in the U.S.?
VERBATIM ANSWER: We recognize the need for additional tests for influenza, particularly over-the-counter tests and point-of-care tests, including respiratory panels with COVID-19. We will continue to tailor our validation recommendations to best serve public health needs. We have provided recommendations in our EUA templates, pre-EUA, and Pre-Submission responses, and it is important to note that these are recommendations provided at a single point in time based on the available information at that time. They are not requirements, as Tim has mentioned, and we are open to alternate approaches to demonstrate performance of your test. We encourage discussion of flu test validation as part of a Pre-Submission and with your lead reviewer, since this is an evolving issue. The recently-issued EUA for the OTC Lucira COVID-19 and flu home test included data from 94 subjects determined positive for influenza A by the comparator method and 0 subjects positive for flu B from the prospectively collected clinical samples. Banked patient samples collected in transfer media were used to establish test performance with flu B due to the low prevalence in the clinical study population and across the US, as reported by CDC. As part of the conditions for authorization, the clinical performance of this test must be further evaluated in an FDA agreed-upon clinical study. The goal of such a study will be to establish performance for flu B in a clinical study with prospective samples. Due to the low levels of flu B in the past few seasons, we are adjusting our general recommendations for developers to target at least 30 influenza-B-positive subjects in a prospective clinical study to support CLIA waiver or over-the-counter IVD indications. This differs from feedback developers may have previously received, such as in Q-Submissions. These previous recommendations for testing included a target of 120 subjects positive by the comparator method for flu B to support CLIA waiver and OTC IVD indications. Again, we encourage developers to continue engaging with us on this topic.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: flu B validation, low prevalence, FDA recommendations
REVIEW FLAG: False

QA Block 2-8
CLARIFIED QUESTION: What were the conditions for authorization for the Lucira COVID-19 and flu home test related to flu validation?
CLARIFIED ANSWER: The Lucira COVID-19 and flu home test received emergency use authorization with conditions requiring further clinical performance evaluation for flu B in an FDA-agreed study using prospective samples.
VERBATIM QUESTION: What were the conditions for authorization for the Lucira COVID-19 and flu home test related to flu validation?
VERBATIM ANSWER: The recently-issued EUA for the OTC Lucira COVID-19 and flu home test included data from 94 subjects determined positive for influenza A by the comparator method and 0 subjects positive for flu B from the prospectively collected clinical samples. Banked patient samples collected in transfer media were used to establish test performance with flu B due to the low prevalence in the clinical study population and across the US, as reported by CDC. As part of the conditions for authorization, the clinical performance of this test must be further evaluated in an FDA agreed-upon clinical study. The goal of such a study will be to establish performance for flu B in a clinical study with prospective samples.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: Lucira test authorization, flu B validation, FDA conditions
REVIEW FLAG: False

QA Block 2-10
CLARIFIED QUESTION: What is the relationship between the expiry of the 319 public health emergency and the continuation of the 564 EUA declaration?
CLARIFIED ANSWER: The expiration of the 319 public health emergency does not affect the continuation of the 564 EUA declaration, as they are independent. The 564 EUA remains in effect until terminated by the Secretary of HHS, and 180 days notice is anticipated before such termination.
VERBATIM QUESTION: What is the relationship between the expiry of the 319 public health emergency and the continuation of the 564 EUA declaration?
VERBATIM ANSWER: As we've discussed previously on the town halls and mentioned in the last town hall, the administration has announced that the public health emergency under 319 will expire on May 11 and will not be renewed. We've also discussed on previous town halls and in our FAQs on our website that the 319 and the 564 declarations are independent, and the 319 public health emergency expiration does not impact the 564 declaration, which is what gives us the authority to issue emergency use authorizations. The COVID-19 EUA declaration under Section 564 of the FD&C Act will continue until the Secretary of HHS terminates it. And as is discussed in the draft transition plan guidance, we do expect 180 days notice before that 564 EUA declaration is terminated.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: 319 public health emergency, 564 EUA declaration, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 2-11
CLARIFIED QUESTION: How will manufacturers of EUA-authorized COVID-19 tests transition to normal operations once the 564 declaration ends?
CLARIFIED ANSWER: Manufacturers with EUA-authorized tests will be provided 180 days' notice before the termination of the 564 declaration. FDA plans to allow continued distribution of these tests while manufacturers' traditional marketing submissions are under review, with full details to be outlined in forthcoming final guidance.
VERBATIM QUESTION: How will manufacturers of EUA-authorized COVID-19 tests transition to normal operations once the 564 declaration ends?
VERBATIM ANSWER: The COVID-19 EUA declaration under Section 564 of the FD&C Act will continue until the Secretary of HHS terminates it. And as is discussed in the draft transition plan guidance, we do expect 180 days notice before that 564 EUA declaration is terminated. We don't plan to take any action that would leave Americans without the tests that they need, and we recognize the need for manufacturers of tests that were issued EUAs to have an appropriate period of transition time to move to normal operations when the declaration under 564 is no longer in effect. The draft transition plan guidance discusses that FDA intends to implement policies for continued distribution of tests previously issued an EUA while the manufacturer's traditional marketing submission is under review. And the final details for that will be described in the final transition plan guidance when issued.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA test transition, 564 declaration termination, FDA guidance plans
REVIEW FLAG: False

QA Block 2-12
CLARIFIED QUESTION: Will the FDA allow continued distribution of tests under EUA while their traditional marketing submissions are being reviewed?
CLARIFIED ANSWER: The FDA plans to allow continued distribution of previously authorized EUA tests while their traditional marketing submissions are under review, with further details in the final transition plan guidance.
VERBATIM QUESTION: Will the FDA allow continued distribution of tests under EUA while their traditional marketing submissions are being reviewed?
VERBATIM ANSWER: The draft transition plan guidance discusses that FDA intends to implement policies for continued distribution of tests previously issued an EUA while the manufacturer's traditional marketing submission is under review. And the final details for that will be described in the final transition plan guidance when issued.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA transition plan, Test distribution policies, FDA marketing submissions
REVIEW FLAG: False

QA Block 2-13
CLARIFIED QUESTION: What is the timeline for the publication of the final transition plan guidance?
CLARIFIED ANSWER: The FDA expects the final transition plan guidance to be published very soon, as OMB has completed their review.
VERBATIM QUESTION: What is the timeline for the publication of the final transition plan guidance?
VERBATIM ANSWER: And you may have seen on the OMB website that OMB has completed their review of the final transition plan guidances, so we do expect them to publish very soon.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Transition guidance timeline, FDA policy updates
REVIEW FLAG: False

QA Block 2-14
CLARIFIED QUESTION: What actions should test developers take if they are currently planning their COVID-19 test submissions post-transition?
CLARIFIED ANSWER: Test developers planning COVID-19 submissions post-transition should email COVID19Dx@fda.hhs.gov for guidance or submit a pre-submission, like de novo or 510k, to discuss their plans with FDA.
VERBATIM QUESTION: What actions should test developers take if they are currently planning their COVID-19 test submissions post-transition?
VERBATIM ANSWER: As always, if you have specific questions about how to manage your current plans for your COVID-19 test, you can always send an email to COVID19Dx@fda.hhs.gov or submit a pre-submission, as Tim was discussing, if you're considering submitting a de novo or a 510k.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: COVID-19 test submissions, FDA guidance, Transition planning
REVIEW FLAG: False

QA Block 2-15
CLARIFIED QUESTION: What are the FDA's considerations for using a comparator cleared more than five years ago for flu testing?
CLARIFIED ANSWER: FDA recommends using a highly-sensitive, FDA-cleared, RT-PCR test cleared within five years for flu testing, but may consider older comparators if data supports unchanged performance with current flu strains, such as through an in silico analysis.
VERBATIM QUESTION: What are the FDA's considerations for using a comparator cleared more than five years ago for flu testing?
VERBATIM ANSWER: To support a multi-analyte respiratory panel, we recommend that the comparative method for flu be a highly-sensitive, FDA-cleared, RT-PCR test, and typically we recommend that this is cleared within the past five years. However, we may consider a comparator that has been cleared previous to that time frame if you can demonstrate that the test performance is expected to remain unchanged with currently circulating flu strains; for example, providing an in silico analysis of the primers and probes, including contemporary strains.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: flu testing, comparator use, validation requirements
REVIEW FLAG: False

QA Block 2-16
CLARIFIED QUESTION: What is the updated target for influenza B-positive subjects in a prospective clinical study for CLIA waiver or OTC indications, and how does it differ from previous recommendations?
CLARIFIED ANSWER: The FDA now recommends targeting at least 30 influenza-B-positive subjects for prospective clinical studies supporting CLIA waiver or OTC indications, a reduction from the prior target of 120 subjects.
VERBATIM QUESTION: What is the updated target for influenza B-positive subjects in a prospective clinical study for CLIA waiver or OTC indications, and how does it differ from previous recommendations?
VERBATIM ANSWER: Due to the low levels of flu B in the past few seasons, we are adjusting our general recommendations for developers to target at least 30 influenza-B- positive subjects in a prospective clinical study to support CLIA waiver or over-the-counter IVD indications. This differs from feedback developers may have previously received, such as in Q- Submissions. These previous recommendations for testing included a target of 120 subjects positive by the comparator method for flu B to support CLIA waiver and OTC IVD indications.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: Updated target for influenza B-positive subjects, CLIA waiver or OTC indications, FDA recommendation changes
REVIEW FLAG: False


#### 3. COVID-19 Antigen Test Submission Pathways and Regulations

QA Block 3-1
CLARIFIED QUESTION: Can an over-the-counter COVID-19 antigen test be submitted through the 510(k) pathway now using Quidel's Sofia 2 test as the predicate device?
CLARIFIED ANSWER: The Quidel Sofia 2 test is cleared only for point-of-care use. Over-the-counter COVID-19 antigen tests cannot yet use it as a predicate device in the 510(k) pathway. FDA would need to first grant authorization for an over-the-counter test via the de novo pathway.
VERBATIM QUESTION: Can an over-the-counter COVID-19 antigen test be submitted through the 510(k) pathway now using Quidel's Sofia 2 test as the predicate device?
VERBATIM ANSWER: No, the Quidel Sofia 2 test is cleared only for point-of-care use, not over-the-counter. And the regulation and special controls were drafted for point-of-care use. While we have not yet granted full marketing authorization for an at-home over-the-counter COVID-19 antigen test, we are interested in doing so, and the first such test would need to be granted through the de novo pathway.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: COVID-19 antigen tests, 510(k) pathway, de novo pathway
REVIEW FLAG: False

QA Block 3-2
CLARIFIED QUESTION: What is the process for receiving FDA feedback for questions that are too detailed for the town hall?
CLARIFIED ANSWER: If a question is too detailed or case-specific for the town hall, the FDA will try to provide a written response within a few days. If no response is received, individuals can follow up via specified email addresses or contact their lead reviewer for pre-EUA or pre-submission related questions.
VERBATIM QUESTION: What is the process for receiving FDA feedback for questions that are too detailed for the town hall?
VERBATIM ANSWER: We do receive some emailed questions that are too detailed or test case-specific that we will not address during today's town hall. For those questions, we will try to send a response in writing within a few days. If you have submitted a question and do not hear it addressed today, please look for a written response. If you do not receive a written response in a few days, please feel free to reach back out to us at MPXDx@fda.hhs.gov email box or to COVID19Dx@fda.hhs.gov mailbox for an update. Also, we have received some specific questions as a follow-up to FDA feedback from the pre-emergency-use authorization or pre-submission requests that we will not address during today's virtual town hall. For these questions, we encourage you to contact your assigned lead reviewer to discuss or submit a supplemental request.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Joseph Tartal (FDA)
TOPICS: FDA feedback process, Detailed questions, Pre-EUA/pre-submission follow-up
REVIEW FLAG: False

QA Block 3-3
CLARIFIED QUESTION: How should test developers follow up on unanswered questions sent to the FDA for the town hall?
CLARIFIED ANSWER: FDA advises test developers to await a written response for unanswered questions after the town hall, and if no response is received within a few days, they should follow up via the provided email addresses.
VERBATIM QUESTION: How should test developers follow up on unanswered questions sent to the FDA for the town hall?
VERBATIM ANSWER: Please note, we do receive some emailed questions that are too detailed or test case-specific that we will not address during today's town hall. For those questions, we will try to send a response in writing within a few days. If you have submitted a question and do not hear it addressed today, please look for a written response. If you do not receive a written response in a few days, please feel free to reach back out to us at MPXDx@fda.hhs.gov email box or to COVID19Dx@fda.hhs.gov mailbox for an update.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Joseph Tartal (FDA)
TOPICS: unanswered questions, FDA follow-ups, email contact
REVIEW FLAG: False

QA Block 3-4
CLARIFIED QUESTION: What happens to follow-up questions arising from pre-EUA or pre-submission feedback if they are not addressed during a town hall?
CLARIFIED ANSWER: FDA advises contacting the assigned lead reviewer or submitting a supplemental request to address follow-up questions originating from pre-EUA or pre-submission feedback if they are not covered during the town hall.
VERBATIM QUESTION: What happens to follow-up questions arising from pre-EUA or pre-submission feedback if they are not addressed during a town hall?
VERBATIM ANSWER: Also, we have received some specific questions as a follow-up to FDA feedback from the pre-emergency-use authorization or pre-submission requests that we will not address during today's virtual town hall. For these questions, we encourage you to contact your assigned lead reviewer to discuss or submit a supplemental request.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Joseph Tartal (FDA)
TOPICS: Follow-up questions, Pre-EUA feedback, Pre-submission process
REVIEW FLAG: False

QA Block 3-5
CLARIFIED QUESTION: What steps should a developer take if they do not receive a timely written response from the FDA after submitting a question?
CLARIFIED ANSWER: Developers should follow up by contacting FDA via the MPXDx@fda.hhs.gov or COVID19Dx@fda.hhs.gov email addresses if they do not receive a written response within a few days.
VERBATIM QUESTION: What steps should a developer take if they do not receive a timely written response from the FDA after submitting a question?
VERBATIM ANSWER: If you do not receive a written response in a few days, please feel free to reach back out to us at MPXDx@fda.hhs.gov email box or to COVID19Dx@fda.hhs.gov mailbox for an update.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Joseph Tartal (FDA)
TOPICS: Follow-up steps for FDA communication, FDA contact information
REVIEW FLAG: False

QA Block 3-6
CLARIFIED QUESTION: What is the de novo process for granting marketing authorization for over-the-counter COVID-19 antigen tests?
CLARIFIED ANSWER: FDA has not yet granted full marketing authorization for any over-the-counter COVID-19 antigen tests, but the first such test would need to be approved through the de novo pathway.
VERBATIM QUESTION: What is the de novo process for granting marketing authorization for over-the-counter COVID-19 antigen tests?
VERBATIM ANSWER: No, the Quidel Sofia 2 test is cleared only for point-of-care use, not over-the- counter. And the regulation and special controls were drafted for point-of-care use. While we have not yet granted full marketing authorization for an at-home over-the-counter COVID-19 antigen test, we are interested in doing so, and the first such test would need to be granted through the de novo pathway.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: de novo pathway, COVID-19 antigen test, over-the-counter testing
REVIEW FLAG: False

QA Block 3-7
CLARIFIED QUESTION: Are there plans for the FDA to establish specific regulations and special controls for at-home over-the-counter COVID-19 antigen tests similar to those for point-of-care tests?
CLARIFIED ANSWER: The FDA has not yet authorized at-home over-the-counter COVID-19 antigen tests. Regulations for point-of-care tests differ, and the first at-home test would require authorization through the de novo pathway.
VERBATIM QUESTION: Are there plans for the FDA to establish specific regulations and special controls for at-home over-the-counter COVID-19 antigen tests similar to those for point-of-care tests?
VERBATIM ANSWER: No, the Quidel Sofia 2 test is cleared only for point-of-care use, not over-the- counter. And the regulation and special controls were drafted for point-of-care use. While we have not yet granted full marketing authorization for an at-home over-the-counter COVID-19 antigen test, we are interested in doing so, and the first such test would need to be granted through the de novo pathway.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Over-the-counter COVID-19 tests, FDA regulations, de novo pathway
REVIEW FLAG: False


#### 4. Safety Considerations for At-Home SARS-CoV-2 Test Development

QA Block 4-1
CLARIFIED QUESTION: Is it acceptable to include guanidine hydrochloride in an at-home SARS-CoV-2 test?
CLARIFIED ANSWER: The FDA advises against using guanidinium salts in at-home devices unless sufficient safety measures are implemented. Detailed design information and labeling should be submitted for FDA review to evaluate risks and mitigations.
VERBATIM QUESTION: Is it acceptable to include guanidine hydrochloride in an at-home SARS-CoV-2 test?
VERBATIM ANSWER: Hazardous or irritating materials, such as guanidinium salts, should not be used for at-home devices unless the device has specific safety features to mitigate the risk of patient exposure. That might be, for example, releasing the preservative only when the container's lid is closed. We recommend that you provide the FDA with detailed design information, including images and a list of all reagents and concentrations, for an assessment of the toxicology profile of the components of your assay. We also recommend that your proposed assay labeling inform users of the risks associated with the use of your device as well as any recommendations for personal protective equipment. We recommend that you specify the volumes and concentrations of each reagent included in your test kit, and FDA will conduct an independent risk assessment to determine if the proposed mitigations are appropriate.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Guanidine hydrochloride use, Safety measures for at-home tests, FDA risk assessment
REVIEW FLAG: False

QA Block 4-2
CLARIFIED QUESTION: What safety features should be included to mitigate the risk of patient exposure to hazardous materials in at-home test devices?
CLARIFIED ANSWER: FDA advises including safety features like releasing preservatives only when the lid is closed to mitigate risks. Provide detailed design information and labeling to highlight risks, reagent specifics, and PPE guidance. FDA will assess the toxicology and determine risk mitigation appropriateness.
VERBATIM QUESTION: What safety features should be included to mitigate the risk of patient exposure to hazardous materials in at-home test devices?
VERBATIM ANSWER: Hazardous or irritating materials, such as guanidinium salts, should not be used for at-home devices unless the device has specific safety features to mitigate the risk of patient exposure. That might be, for example, releasing the preservative only when the container's lid is closed. We recommend that you provide the FDA with detailed design information, including images and a list of all reagents and concentrations, for an assessment of the toxicology profile of the components of your assay. We also recommend that your proposed assay labeling inform users of the risks associated with the use of your device as well as any recommendations for personal protective equipment. We recommend that you specify the volumes and concentrations of each reagent included in your test kit, and FDA will conduct an independent risk assessment to determine if the proposed mitigations are appropriate.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: safety features for hazardous materials, at-home test device guidelines, FDA risk assessment
REVIEW FLAG: False

QA Block 4-3
CLARIFIED QUESTION: What specific design details should be submitted to the FDA for the assessment of hazardous materials in test components?
CLARIFIED ANSWER: The FDA recommends providing detailed design information, including images, a list of all reagents and concentrations, and the volumes of each reagent. Additionally, proposed assay labeling should inform users of risks and include any safety recommendations. FDA will independently assess the toxicology profile and risk mitigation measures.
VERBATIM QUESTION: What specific design details should be submitted to the FDA for the assessment of hazardous materials in test components?
VERBATIM ANSWER: We recommend that you provide the FDA with detailed design information, including images and a list of all reagents and concentrations, for an assessment of the toxicology profile of the components of your assay. We also recommend that your proposed assay labeling inform users of the risks associated with the use of your device as well as any recommendations for personal protective equipment. We recommend that you specify the volumes and concentrations of each reagent included in your test kit, and FDA will conduct an independent risk assessment to determine if the proposed mitigations are appropriate.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: design details for FDA assessment, toxicology profile, assay labeling
REVIEW FLAG: False

QA Block 4-5
CLARIFIED QUESTION: What recommendations for personal protective equipment should be included in the labeling of at-home test devices involving hazardous materials?
CLARIFIED ANSWER: FDA recommends that labeling for at-home test devices involving hazardous materials should inform users about associated risks and provide instructions on necessary personal protective equipment.
VERBATIM QUESTION: What recommendations for personal protective equipment should be included in the labeling of at-home test devices involving hazardous materials?
VERBATIM ANSWER: We recommend that your proposed assay labeling inform users of the risks associated with the use of your device as well as any recommendations for personal protective equipment.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: PPE recommendations, Labeling for hazardous materials
REVIEW FLAG: False

QA Block 4-6
CLARIFIED QUESTION: What happens during the FDA's independent risk assessment of an at-home test device's proposed safety mitigations?
CLARIFIED ANSWER: FDA will assess the safety of the test kit by examining details such as reagent volumes and concentrations to ensure the proposed mitigations are adequate.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: We recommend that you specify the volumes and concentrations of each reagent included in your test kit, and FDA will conduct an independent risk assessment to determine if the proposed mitigations are appropriate.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: FDA risk assessment, at-home test safety, toxicology profile
REVIEW FLAG: False


#### 5. COVID-19 Test Regulations and Product Code Updates

QA Block 5-1
CLARIFIED QUESTION: Will the FDA update the code QMN in the product classification database given the encouragement for manufacturers to avoid the EUA route?
CLARIFIED ANSWER: Existing product codes, including QMN, will remain designated as EUA product codes. New codes will be added for tests granted FDA clearance under traditional authorization pathways, which are highlighted on the molecular and antigen EUA web pages.
VERBATIM QUESTION: Will the FDA update the code QMN in the product classification database given the encouragement for manufacturers to avoid the EUA route?
VERBATIM ANSWER: The product codes that are existing will not be changed. They will remain as EUA product codes, and product codes will be added as new premarket submissions are granted or FDA cleared. You can also see on the molecular EUA web page and the antigen EUA web page, there's a blue box above the table of EUA tests, and that blue box points to the de novo and 510k databases and lists the procodes for the tests that have received authorization through the traditional premarket authorization pathways, de novo and 510k.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: FDA product codes, COVID-19 test classifications, EUA vs traditional pathways
REVIEW FLAG: False

QA Block 5-2
CLARIFIED QUESTION: How will newly approved COVID-19 tests be categorized if traditional premarket authorization pathways are used?
CLARIFIED ANSWER: Existing product codes will remain EUA codes, while new product codes will be added for tests authorized under traditional premarket pathways such as de novo and 510k. These can be found via links in the EUA web pages.
VERBATIM QUESTION: How will newly approved COVID-19 tests be categorized if traditional premarket authorization pathways are used?
VERBATIM ANSWER: The product codes that are existing will not be changed. They will remain as EUA product codes, and product codes will be added as new premarket submissions are granted or FDA cleared. You can also see on the molecular EUA web page and the antigen EUA web page, there's a blue box above the table of EUA tests, and that blue box points to the de novo and 510k databases and lists the procodes for the tests that have received authorization through the traditional premarket authorization pathways, de novo and 510k.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: COVID-19 test categorization, premarket pathways, EUA and traditional pathways
REVIEW FLAG: False

QA Block 5-3
CLARIFIED QUESTION: Where can test developers find information on procodes for COVID-19 tests approved under the 510(k) or de novo pathways?
CLARIFIED ANSWER: Test developers can find procodes for COVID-19 tests approved under the 510(k) or de novo pathways on the molecular EUA and antigen EUA web pages, specifically in the blue box above the EUA test table which links to the relevant databases.
VERBATIM QUESTION: Where can test developers find information on procodes for COVID-19 tests approved under the 510(k) or de novo pathways?
VERBATIM ANSWER: You can also see on the molecular EUA web page and the antigen EUA web page, there's a blue box above the table of EUA tests, and that blue box points to the de novo and 510k databases and lists the procodes for the tests that have received authorization through the traditional premarket authorization pathways, de novo and 510k.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: COVID-19 test procodes, 510(k) and de novo pathways, FDA resources
REVIEW FLAG: False

QA Block 5-4
CLARIFIED QUESTION: Will product codes be created for COVID-19 tests that transition from EUA to regular market authorization?
CLARIFIED ANSWER: Existing product codes will remain as EUA codes. New product codes will be created for COVID-19 tests authorized through traditional premarket pathways such as de novo and 510k.
VERBATIM QUESTION: Will product codes be created for COVID-19 tests that transition from EUA to regular market authorization?
VERBATIM ANSWER: The product codes that are existing will not be changed. They will remain as EUA product codes, and product codes will be added as new premarket submissions are granted or FDA cleared. You can also see on the molecular EUA web page and the antigen EUA web page, there's a blue box above the table of EUA tests, and that blue box points to the de novo and 510k databases and lists the procodes for the tests that have received authorization through the traditional premarket authorization pathways, de novo and 510k.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Product codes, EUA vs. premarket authorization, COVID-19 tests
REVIEW FLAG: False


#### 6. FDA Guidance on Single-Target vs. Multi-Target COVID Tests

QA Block 6-1
CLARIFIED QUESTION: Can the FDA comment on the current thinking regarding single-target COVID tests for emergency use authorization now that there is a large database of genomic information available for manufacturers to utilize in the design of IVD tests?
CLARIFIED ANSWER: FDA has observed performance changes over time in EUA tests as new variants emerge, leading to a public health risk if mutations occur in test-targeted regions. Single-target tests face greater susceptibility to such impacts compared to multiple-target tests. Additional labeling mitigations addressing these risks would likely be required for single-target tests.
VERBATIM QUESTION: Can the FDA comment on the current thinking regarding single-target COVID tests for emergency use authorization now that there is a large database of genomic information available for manufacturers to utilize in the design of IVD tests?
VERBATIM ANSWER: As the COVID pandemic has progressed, we've observed changes in EUA test performance as new variants emerge. We have a good deal of information on our website about that. And there is a risk to public health if test performance changes as new variants harboring mutations in regions targeted by a molecular test emerge. In general, tests that detect multiple SARS-CoV-2 targets have a lower probability of being impacted by mutations when compared with tests capable of detecting only one target region. It's likely appropriate that users of single-target tests be made aware of this risk through additional mitigations. So we would likely require additional labeling mitigations, so information in the product labeling about the risk of impact by mutations. And multiple target tests likely would not need these additional labeling mitigations.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Single-target COVID tests, Emergency use authorization, Impact of viral mutations on tests
REVIEW FLAG: False

QA Block 6-2
CLARIFIED QUESTION: Would it be acceptable to use a single-target COVID test approach for future premarket submissions?
CLARIFIED ANSWER: The FDA notes that single-target COVID tests pose a higher risk of performance changes due to mutations. Therefore, additional labeling mitigations would likely be required for single-target tests, whereas multiple-target tests would not need such mitigations.
VERBATIM QUESTION: Would it be acceptable to use a single-target COVID test approach for future premarket submissions?
VERBATIM ANSWER: As the COVID pandemic has progressed, we've observed changes in EUA test performance as new variants emerge. We have a good deal of information on our website about that. And there is a risk to public health if test performance changes as new variants harboring mutations in regions targeted by a molecular test emerge. In general, tests that detect multiple SARS-CoV-2 targets have a lower probability of being impacted by mutations when compared with tests capable of detecting only one target region. It's likely appropriate that users of single-target tests be made aware of this risk through additional mitigations. So we would likely require additional labeling mitigations, so information in the product labeling about the risk of impact by mutations. And multiple target tests likely would not need these additional labeling mitigations.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Single-target COVID tests, Premarket submission requirements, Labeling mitigations
REVIEW FLAG: False

QA Block 6-3
CLARIFIED QUESTION: What are the potential risks to public health when using single-target molecular COVID-19 tests as new variants emerge?
CLARIFIED ANSWER: FDA indicates that single-target tests may pose public health risks due to performance changes caused by mutations in targeted regions, while multi-target tests have a lower likelihood of being affected. Additional labeling mitigations may be needed for single-target tests.
VERBATIM QUESTION: What are the potential risks to public health when using single-target molecular COVID-19 tests as new variants emerge?
VERBATIM ANSWER: As the COVID pandemic has progressed, we've observed changes in EUA test performance as new variants emerge. We have a good deal of information on our website about that. And there is a risk to public health if test performance changes as new variants harboring mutations in regions targeted by a molecular test emerge. In general, tests that detect multiple SARS-CoV-2 targets have a lower probability of being impacted by mutations when compared with tests capable of detecting only one target region. It's likely appropriate that users of single-target tests be made aware of this risk through additional mitigations. So we would likely require additional labeling mitigations, so information in the product labeling about the risk of impact by mutations. And multiple target tests likely would not need these additional labeling mitigations.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Single-target test risks, Emerging variants, Test labeling mitigations
REVIEW FLAG: False

QA Block 6-4
CLARIFIED QUESTION: What additional labeling requirements might be necessary for single-target molecular tests to mitigate risks associated with mutations?
CLARIFIED ANSWER: The FDA would likely require additional labeling mitigations for single-target molecular tests to inform users about risks from mutations. These risks are minimized in tests detecting multiple targets, which likely wouldn't require additional labeling.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: As the COVID pandemic has progressed, we've observed changes in EUA test performance as new variants emerge. We have a good deal of information on our website about that. And there is a risk to public health if test performance changes as new variants harboring mutations in regions targeted by a molecular test emerge. In general, tests that detect multiple SARS-CoV-2 targets have a lower probability of being impacted by mutations when compared with tests capable of detecting only one target region. It's likely appropriate that users of single-target tests be made aware of this risk through additional mitigations. So we would likely require additional labeling mitigations, so information in the product labeling about the risk of impact by mutations. And multiple target tests likely would not need these additional labeling mitigations.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Single-target molecular tests, Impact of mutations, Labeling requirements
REVIEW FLAG: False

QA Block 6-5
CLARIFIED QUESTION: Why do multi-target SARS-CoV-2 tests have a lower probability of being affected by new mutations compared to single-target tests?
CLARIFIED ANSWER: Multi-target SARS-CoV-2 tests are less likely to be affected by mutations because they detect multiple regions, reducing the impact if mutations occur in one targeted area.
VERBATIM QUESTION: Why do multi-target SARS-CoV-2 tests have a lower probability of being affected by new mutations compared to single-target tests?
VERBATIM ANSWER: In general, tests that detect multiple SARS-CoV-2 targets have a lower probability of being impacted by mutations when compared with tests capable of detecting only one target region.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: multi-target tests, mutations, test robustness
REVIEW FLAG: False

QA Block 6-6
CLARIFIED QUESTION: Are there publicly available FDA resources regarding changes in test performance as new SARS-CoV-2 variants emerge?
CLARIFIED ANSWER: The FDA provides information on its website about EUA test performance changes as new SARS-CoV-2 variants emerge.
VERBATIM QUESTION: Are there publicly available FDA resources regarding changes in test performance as new SARS-CoV-2 variants emerge?
VERBATIM ANSWER: As the COVID pandemic has progressed, we've observed changes in EUA test performance as new variants emerge. We have a good deal of information on our website about that.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA test performance, SARS-CoV-2 variants, FDA resources
REVIEW FLAG: False

QA Block 6-7
CLARIFIED QUESTION: Can labeling mitigations for single-target tests help ensure adequate performance against emerging variants?
CLARIFIED ANSWER: Labeling mitigations, such as including information about the risk of mutations in product labeling, are likely required for single-target SARS-CoV-2 tests to ensure users understand the risks and maintain adequate performance against emerging variants.
VERBATIM QUESTION: Can labeling mitigations for single-target tests help ensure adequate performance against emerging variants?
VERBATIM ANSWER: As the COVID pandemic has progressed, we've observed changes in EUA test performance as new variants emerge. We have a good deal of information on our website about that. And there is a risk to public health if test performance changes as new variants harboring mutations in regions targeted by a molecular test emerge. In general, tests that detect multiple SARS-CoV-2 targets have a lower probability of being impacted by mutations when compared with tests capable of detecting only one target region. It's likely appropriate that users of single-target tests be made aware of this risk through additional mitigations. So we would likely require additional labeling mitigations, so information in the product labeling about the risk of impact by mutations. And multiple target tests likely would not need these additional labeling mitigations.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: labeling mitigations, single-target molecular tests, variant impact on test performance
REVIEW FLAG: False


#### 7. Recommendations for Addressing Flu B Performance Validation Challenges

QA Block 7-1
CLARIFIED QUESTION: What recommendations do you have if a sponsor does not have retrospective samples to demonstrate flu B performance due to low prevalence?
CLARIFIED ANSWER: FDA suggests collecting flu B samples from the Southern Hemisphere due to higher prevalence there or using alternate means for EUA validation. Sponsors may propose to disable the flu B signal for validation, either via antigen cover masking or molecular test electronic modifications.
VERBATIM QUESTION: What recommendations do you have if a sponsor does not have retrospective samples to demonstrate flu B performance due to low prevalence?
VERBATIM ANSWER: So first of all, the flu season is picking up in the Southern hemisphere. And very frequently, flu B is more prevalent in the Southern hemisphere. So that is one pathway to collect flu B samples. If we're talking about an EUA-- so that would be an EUA that's combined with COVID-- we will be relatively flexible about how we do this by alternate means. But we do need to understand flu performance in some way. An alternate approach is to potentially turn off the flu B signal in some way. If it's an antigen test, it can be masked with a change to the cover. Or if it's a molecular test, sometimes that can be done by electronic means, if it's an electronic readout. So come in with a proposal about how we can-- how you can validate this for discussion.
SPEAKER QUESTION: Kal Mansoor
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Flu B performance validation, EUA flexibility, Alternate sample collection methods
REVIEW FLAG: False

QA Block 7-2
CLARIFIED QUESTION: How can flu B samples be collected from the Southern hemisphere if prevalence is higher there?
CLARIFIED ANSWER: Flu B samples can be collected from the Southern hemisphere where flu B prevalence is often higher during their flu season.
VERBATIM QUESTION: How can flu B samples be collected from the Southern hemisphere if prevalence is higher there?
VERBATIM ANSWER: So this is Tim. So first of all, the flu season is picking up in the Southern hemisphere. And very frequently, flu B is more prevalent in the Southern hemisphere. So that is one pathway to collect flu B samples.
SPEAKER QUESTION: Kal Mansoor
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: flu B sample collection, Southern hemisphere prevalence
REVIEW FLAG: False

QA Block 7-3
CLARIFIED QUESTION: What alternate methods to demonstrate flu B performance are acceptable under an EUA for a combined flu and COVID test?
CLARIFIED ANSWER: The FDA suggests collecting flu B samples from the Southern hemisphere where flu B is more prevalent or turning off the flu B signal through various methods (e.g., masking for antigen tests or electronic configuration for molecular tests). Sponsors should propose methods for approval.
VERBATIM QUESTION: What alternate methods to demonstrate flu B performance are acceptable under an EUA for a combined flu and COVID test?
VERBATIM ANSWER: So this is Tim. So first of all, the flu season is picking up in the Southern hemisphere. And very frequently, flu B is more prevalent in the Southern hemisphere. So that is one pathway to collect flu B samples. If we're talking about an EUA-- so that would be an EUA that's combined with COVID-- we will be relatively flexible about how we do this by alternate means. But we do need to understand flu performance in some way. An alternate approach is to potentially turn off the flu B signal in some way. If it's an antigen test, it can be masked with a change to the cover. Or if it's a molecular test, sometimes that can be done by electronic means, if it's an electronic readout. So come in with a proposal about how we can-- how you can validate this for discussion.
SPEAKER QUESTION: Kal Mansoor
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: flu B sample collection methods, EUA flexibility, validation proposals
REVIEW FLAG: False

QA Block 7-4
CLARIFIED QUESTION: How can a developer turn off or mask a flu B signal in an antigen test to address validation challenges?
CLARIFIED ANSWER: A developer can turn off the flu B signal in an antigen test by masking it, possibly by changing the cover. For molecular tests, this may be done electronically if the readout is electronic. FDA encourages submitting a validation proposal for discussion.
VERBATIM QUESTION: How can a developer turn off or mask a flu B signal in an antigen test to address validation challenges?
VERBATIM ANSWER: An alternate approach is to potentially turn off the flu B signal in some way. If it's an antigen test, it can be masked with a change to the cover. Or if it's a molecular test, sometimes that can be done by electronic means, if it's an electronic readout. So come in with a proposal about how we can-- how you can validate this for discussion.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Flu B masking, Antigen test validation, Electronic readout modifications
REVIEW FLAG: False

QA Block 7-5
CLARIFIED QUESTION: What options are available for electronically masking flu B signals in molecular tests?
CLARIFIED ANSWER: Flu B signals in molecular tests can potentially be electronically masked if the readout is electronic.
VERBATIM QUESTION: What options are available for electronically masking flu B signals in molecular tests?
VERBATIM ANSWER: An alternate approach is to potentially turn off the flu B signal in some way. If it's an antigen test, it can be masked with a change to the cover. Or if it's a molecular test, sometimes that can be done by electronic means, if it's an electronic readout.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: flu B signal masking, molecular tests
REVIEW FLAG: False

QA Block 7-6
CLARIFIED QUESTION: What should be included in a proposal to validate flu B performance when samples are limited?
CLARIFIED ANSWER: FDA suggests sponsors collect flu B samples from regions where flu B is prevalent, such as the Southern hemisphere during the flu season. For EUA combined with COVID-19 tests, FDA allows flexible alternate approaches, such as turning off the flu B signal electronically or masking it for antigen tests. Sponsors are encouraged to submit a proposal for validation discussion.
VERBATIM QUESTION: What should be included in a proposal to validate flu B performance when samples are limited?
VERBATIM ANSWER: So this is Tim. So first of all, the flu season is picking up in the Southern hemisphere. And very frequently, flu B is more prevalent in the Southern hemisphere. So that is one pathway to collect flu B samples. If we're talking about an EUA-- so that would be an EUA that's combined with COVID-- we will be relatively flexible about how we do this by alternate means. But we do need to understand flu performance in some way. An alternate approach is to potentially turn off the flu B signal in some way. If it's an antigen test, it can be masked with a change to the cover. Or if it's a molecular test, sometimes that can be done by electronic means, if it's an electronic readout. So come in with a proposal about how we can-- how you can validate this for discussion.
SPEAKER QUESTION: Kal Mansoor
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation of flu B performance, Alternate sample collection methods, EUA flexibility
REVIEW FLAG: False


#### 8. Acceptable Order of Sample Collection in Clinical Studies

QA Block 8-2
CLARIFIED QUESTION: If the standard of care at a clinical site is to first test with an FDA EUA at-home antigen test, then collect a comparator method test swab, and then collect the candidate test's sample, is this order of collection acceptable?
CLARIFIED ANSWER: Yes, the proposed collection order is acceptable as long as standard of care procedures are followed per IRB recommendations, including any required washout periods between collections. This can be further clarified via the pre-EUA or Q-Sub processes.
VERBATIM QUESTION: If the standard of care at a clinical site is to first test with an FDA EUA at-home antigen test, then collect a comparator method test swab, and then collect the candidate test's sample, is this order of collection acceptable?
VERBATIM ANSWER: Yes. You do need to follow standard of care procedures per IRB recommendations, when appropriate. That can be a molecular rather than, necessarily, an antigen test. But obviously, it takes longer to get that molecular result back than an on-site antigen test. You can pause between collections, particularly between the molecular comparator collection and the candidate test collection, to allow what we call a washout period. Or we've seen in developers, sponsors of studies wait 15 minutes in between collections, and to date I'm not aware of any challenges that put any of the comparisons at a disadvantage. And you can also address this, if you wish, through, if it's an EUA submission, through the pre-EUA process or a Q-Sub if it's for a full authorization process.
SPEAKER QUESTION: Mary V
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: sample collection order, COVID-19 diagnostic tests, FDA EUA compliance
REVIEW FLAG: False

QA Block 8-3
CLARIFIED QUESTION: What is the recommended duration for a washout period between the molecular comparator collection and the candidate test collection?
CLARIFIED ANSWER: FDA recommends a washout period between molecular comparator and candidate test collection, typically around 15 minutes, which has not caused any known disadvantages in comparative studies.
VERBATIM QUESTION: What is the recommended duration for a washout period between the molecular comparator collection and the candidate test collection?
VERBATIM ANSWER: You can pause between collections, particularly between the molecular comparator collection and the candidate test collection, to allow what we call a washout period. Or we've seen in developers, sponsors of studies wait 15 minutes in between collections, and to date I'm not aware of any challenges that put any of the comparisons at a disadvantage.
SPEAKER QUESTION: Mary V
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: washout period duration, molecular comparator collection, candidate test collection
REVIEW FLAG: False

QA Block 8-4
CLARIFIED QUESTION: Are there differences in regulatory submission processes between EUA submissions and full authorization processes in terms of sample collection protocols?
CLARIFIED ANSWER: FDA recommends using the pre-EUA process for EUA submissions or a Q-Sub for full authorization to address sample collection protocols. A washout period between sample collections is also acceptable.
VERBATIM QUESTION: Are there differences in regulatory submission processes between EUA submissions and full authorization processes in terms of sample collection protocols?
VERBATIM ANSWER: You can pause between collections, particularly between the molecular comparator collection and the candidate test collection, to allow what we call a washout period. Or we've seen in developers, sponsors of studies wait 15 minutes in between collections, and to date I'm not aware of any challenges that put any of the comparisons at a disadvantage. And you can also address this, if you wish, through, if it's an EUA submission, through the pre-EUA process or a Q-Sub if it's for a full authorization process.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA vs full authorization, Sample collection protocols, Regulatory submissions
REVIEW FLAG: False

QA Block 8-5
CLARIFIED QUESTION: How have concerns about training users to self-collect nasal swab samples evolved since the beginning of the pandemic?
CLARIFIED ANSWER: Earlier in the pandemic, the FDA was concerned about users needing healthcare providers to train them on nasal swab collection. However, with widespread usage of home tests, this concern has diminished as many people are now experienced with self-collection. The focus has shifted to test performance.
VERBATIM QUESTION: How have concerns about training users to self-collect nasal swab samples evolved since the beginning of the pandemic?
VERBATIM ANSWER: I guess the only thing that I would add is, at the beginning, or earlier in the pandemic, we were concerned with users being taught how to collect a nasal swab by that health care provider prior to self-collecting. And so I think now that we have half-- excuse me-- a billion tests distributed and more on the way, I think that concern is a little bit less. So as Tim mentioned, come in with a Pre-Sub and let us know how you plan to collect those samples. But I think that information has influenced our study recommendations. So traditionally, we've been concerned about bias introduced from a health care professional collecting the sample prior to a self test. And now for home respiratory testing, at least, it's hard to imagine that there's any person left in the United States who can perform the testing on themselves or on somebody else, hasn't done a home test yet. So that pool of unbiased candidate test subjects is not available any longer, and I think people are pretty well-trained on collection and running a test. And so we're then, at this point, focused on the actual performance of the test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Self-collection training, Home testing evolution, Study bias
REVIEW FLAG: False

QA Block 8-6
CLARIFIED QUESTION: Does the FDA still consider the involvement of health care professionals in sample collection as a potential source of bias in clinical studies?
CLARIFIED ANSWER: The FDA previously raised concerns about bias from health care professionals collecting samples before self-testing. Now, with widespread home testing experience, this is less of a concern, and focus is primarily on test performance.
VERBATIM QUESTION: Does the FDA still consider the involvement of health care professionals in sample collection as a potential source of bias in clinical studies?
VERBATIM ANSWER: So traditionally, we've been concerned about bias introduced from a health care professional collecting the sample prior to a self test. And now for home respiratory testing, at least, it's hard to imagine that there's any person left in the United States who can perform the testing on themselves or on somebody else, hasn't done a home test yet. So that pool of unbiased candidate test subjects is not available any longer, and I think people are pretty well-trained on collection and running a test. And so we're then, at this point, focused on the actual performance of the test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Sample collection bias, Home testing experience, Test performance
REVIEW FLAG: False

QA Block 8-7
CLARIFIED QUESTION: To what extent does the widespread distribution of home tests impact current study designs or evaluations for COVID-19 diagnostics?
CLARIFIED ANSWER: The FDA notes that widespread use of home tests has reduced concerns about bias from healthcare-collected samples because most people are now experienced with self-collection. Studies are now focused on test performance.
VERBATIM QUESTION: To what extent does the widespread distribution of home tests impact current study designs or evaluations for COVID-19 diagnostics?
VERBATIM ANSWER: So traditionally, we've been concerned about bias introduced from a health care professional collecting the sample prior to a self test. And now for home respiratory testing, at least, it's hard to imagine that there's any person left in the United States who can perform the testing on themselves or on somebody else, hasn't done a home test yet. So that pool of unbiased candidate test subjects is not available any longer, and I think people are pretty well-trained on collection and running a test. And so we're then, at this point, focused on the actual performance of the test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Impact of home tests, Study design, Test performance
REVIEW FLAG: False

QA Block 8-8
CLARIFIED QUESTION: What are the implications of reduced availability of unbiased candidate test subjects for home respiratory testing studies?
CLARIFIED ANSWER: FDA states that the pool of unbiased candidate test subjects for home respiratory testing no longer exists, as most people in the U.S. are now familiar with self-tests. The focus is currently on the test's performance.
VERBATIM QUESTION: What are the implications of reduced availability of unbiased candidate test subjects for home respiratory testing studies?
VERBATIM ANSWER: So traditionally, we've been concerned about bias introduced from a health care professional collecting the sample prior to a self test. And now for home respiratory testing, at least, it's hard to imagine that there's any person left in the United States who can perform the testing on themselves or on somebody else, hasn't done a home test yet. So that pool of unbiased candidate test subjects is not available any longer, and I think people are pretty well-trained on collection and running a test. And so we're then, at this point, focused on the actual performance of the test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Unbiased candidate test subjects, Home respiratory testing, Test performance
REVIEW FLAG: False


#### 9. Guidance for Clinical Labs Pursuing Test Clearance

QA Block 9-1
CLARIFIED QUESTION: Does the FDA plan to issue specific guidance directed towards clinical laboratories pursuing a 510k or a path to clearance for their institution, specifically for cases where the SARS-CoV-2 test manufacturer is not pursuing clearance?
CLARIFIED ANSWER: FDA encourages clinical laboratories to use the Q-Submission process, which is free, to discuss their unique cases for pursuing clearance. Guidance on the Q-Submission process is available online.
VERBATIM QUESTION: Does the FDA plan to issue specific guidance directed towards clinical laboratories pursuing a 510k or a path to clearance for their institution, specifically for cases where the SARS-CoV-2 test manufacturer is not pursuing clearance?
VERBATIM ANSWER: The FDA has always welcomed lab-developed tests and labs to participate in FDA submissions, and we routinely have been authorizing such tests, even outside of an emergency response. Your specific situation has some inherent challenges, because I take it that it would still be a manufactured test. But you're not the manufacturer, unless you take on the manufacturing role for your own situation. So this is, I think, a perfect example of submitting your plans. And you can do that briefly, and if it's not enough detail, we can ask more questions. You can ask your questions and then submit that as a Pre- Submission or a Q-Submission, and there's no charge for that submission. There is a guidance out there. If you just submit google FDA Q-Submission process, it'll explain in detail how you do that and how you make that submission. It's just a formal way of the FDA receiving a submission electronically and logging it in and opening a file so that we have a record of our responses to you. We endeavor to hold ourselves to the words that we provide in that response to you, to your questions, for when you come back in. So it's all a matter of formal record that we can refer to, and you'll have a formal response that you can refer to as well.
SPEAKER QUESTION: Ray Bandziulis
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA Q-Submission process, Guidance for clinical labs, 510k clearance path
REVIEW FLAG: False

QA Block 9-2
CLARIFIED QUESTION: Can a clinical laboratory act as the sponsor or the manufacturer in a Pre-Submission process while working with the original manufacturer as a supplier?
CLARIFIED ANSWER: Yes, a clinical laboratory can act as the sponsor or manufacturer in such a unique case, and the FDA is willing to discuss finding an appropriate way to address the situation.
VERBATIM QUESTION: Can a clinical laboratory act as the sponsor or the manufacturer in a Pre-Submission process while working with the original manufacturer as a supplier?
VERBATIM ANSWER: Yeah, that's a very unique situation. And I think it's worthy of discussion with the FDA to find a way that we can do that.
SPEAKER QUESTION: Ray Bandziulis
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Pre-Submission process, Clinical laboratory roles, Manufacturer collaboration
REVIEW FLAG: False

QA Block 9-4
CLARIFIED QUESTION: What are the inherent challenges the FDA foresees in a scenario where a test is developed by a lab but the original manufacturer acts as a supplier?
CLARIFIED ANSWER: The FDA notes challenges in situations where a lab uses a manufacturer's test but takes on a manufacturing role without being the original manufacturer. Submitting detailed plans to the FDA for review is recommended.
VERBATIM QUESTION: What are the inherent challenges the FDA foresees in a scenario where a test is developed by a lab but the original manufacturer acts as a supplier?
VERBATIM ANSWER: Your specific situation has some inherent challenges, because I take it that it would still be a manufactured test. But you're not the manufacturer, unless you take on the manufacturing role for your own situation. So this is, I think, a perfect example of submitting your plans.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: lab-developed tests, test manufacturing roles, FDA Pre-Submission process
REVIEW FLAG: False

QA Block 9-5
CLARIFIED QUESTION: What is the significance of submitting plans through a Pre-Submission or Q-Submission for unique scenarios like this?
CLARIFIED ANSWER: Submitting plans through a Pre-Submission or Q-Submission allows the FDA to formally review and respond to unique scenarios, like when labs take on a manufacturing role, while creating a recorded reference of their guidance. The process is free and explained in available FDA guidance.
VERBATIM QUESTION: What is the significance of submitting plans through a Pre-Submission or Q-Submission for unique scenarios like this?
VERBATIM ANSWER: The FDA has always welcomed lab-developed tests and labs to participate in FDA submissions, and we routinely have been authorizing such tests, even outside of an emergency response. Your specific situation has some inherent challenges, because I take it that it would still be a manufactured test. But you're not the manufacturer, unless you take on the manufacturing role for your own situation. So this is, I think, a perfect example of submitting your plans. And you can do that briefly, and if it's not enough detail, we can ask more questions. You can ask your questions and then submit that as a Pre- Submission or a Q-Submission, and there's no charge for that submission. There is a guidance out there. If you just submit google FDA Q-Submission process, it'll explain in detail how you do that and how you make that submission. It's just a formal way of the FDA receiving a submission electronically and logging it in and opening a file so that we have a record of our responses to you. We endeavor to hold ourselves to the words that we provide in that response to you, to your questions, for when you come back in. So it's all a matter of formal record that we can refer to, and you'll have a formal response that you can refer to as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Pre-Submission process, FDA Q-Submission, Unique lab scenarios
REVIEW FLAG: False

QA Block 9-6
CLARIFIED QUESTION: What level of detail should be included when presenting a unique case in a Q-Submission or Pre-Submission to the FDA?
CLARIFIED ANSWER: The FDA suggests submitting a Pre-Submission or Q-Submission briefly detailing your unique case. Additional questions can clarify any gaps. There is formal guidance available online about the FDA's Q-Submission process.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: So this is, I think, a perfect example of submitting your plans. And you can do that briefly, and if it's not enough detail, we can ask more questions. You can ask your questions and then submit that as a Pre- Submission or a Q-Submission, and there's no charge for that submission. There is a guidance out there. If you just submit google FDA Q-Submission process, it'll explain in detail how you do that and how you make that submission. It's just a formal way of the FDA receiving a submission electronically and logging it in and opening a file so that we have a record of our responses to you. We endeavor to hold ourselves to the words that we provide in that response to you, to your questions, for when you come back in. So it's all a matter of formal record that we can refer to, and you'll have a formal response that you can refer to as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Q-Submission process, submission detail expectations, Pre-Submission guidance
REVIEW FLAG: False

QA Block 9-7
CLARIFIED QUESTION: How does the FDA use the formal record created through Q-Submission or Pre-Submission responses in future interactions?
CLARIFIED ANSWER: The FDA uses the formal record created through Q-Submission or Pre-Submission responses to document and refer back to their answers during future interactions, ensuring consistency and providing a formal response for both parties.
VERBATIM QUESTION: How does the FDA use the formal record created through Q-Submission or Pre-Submission responses in future interactions?
VERBATIM ANSWER: It's just a formal way of the FDA receiving a submission electronically and logging it in and opening a file so that we have a record of our responses to you. We endeavor to hold ourselves to the words that we provide in that response to you, to your questions, for when you come back in. So it's all a matter of formal record that we can refer to, and you'll have a formal response that you can refer to as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Q-Submission process, Formal record usage, FDA responses
REVIEW FLAG: False

QA Block 9-8
CLARIFIED QUESTION: What guidance is available for navigating the FDA Q-Submission process?
CLARIFIED ANSWER: FDA has provided guidance on the Q-Submission process, which can be found online by searching 'FDA Q-Submission process.' This explains the submission details, creates a formal record of interactions, and ensures clear, referable responses.
VERBATIM QUESTION: What guidance is available for navigating the FDA Q-Submission process?
VERBATIM ANSWER: There is a guidance out there. If you just submit google FDA Q-Submission process, it'll explain in detail how you do that and how you make that submission. It's just a formal way of the FDA receiving a submission electronically and logging it in and opening a file so that we have a record of our responses to you. We endeavor to hold ourselves to the words that we provide in that response to you, to your questions, for when you come back in. So it's all a matter of formal record that we can refer to, and you'll have a formal response that you can refer to as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA Q-Submission guidance, formal submission process
REVIEW FLAG: False


#### 10. Resolving Lab Notification Issues with the FDA

QA Block 10-1
CLARIFIED QUESTION: Who do I need to contact to get the Promega Clinical Lab (PCL) listed in the lab notification list on the FDA website?
CLARIFIED ANSWER: Email the FDA's COVID-19 inbox (COVID-19Dx@fda.hhs.gov) and request it be forwarded to Kris, Toby, and Tim for assistance in listing the Promega Clinical Lab.
VERBATIM QUESTION: Who do I need to contact to get the Promega Clinical Lab (PCL) listed in the lab notification list on the FDA website?
VERBATIM ANSWER: Yeah. Hey, Deb. So go ahead and send an email to the COVID email box, and ask this be submitted to Kris, Toby, and Tim.
SPEAKER QUESTION: Debs Payne
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: lab notification process, FDA contact information
REVIEW FLAG: False

QA Block 10-2
CLARIFIED QUESTION: Is my reviewer still assigned to me?
CLARIFIED ANSWER: The FDA will review whether your assigned reviewer is still active.
VERBATIM QUESTION: Is my reviewer still assigned to me?
VERBATIM ANSWER: Yeah, we can look at that.
SPEAKER QUESTION: Debs Payne
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: reviewer reassignment, EUA review
REVIEW FLAG: False

QA Block 10-3
CLARIFIED QUESTION: Why might a laboratory not be posted on the lab notification list?
CLARIFIED ANSWER: A laboratory may not appear on the lab notification list if they only submitted an EUA request without prior notification, which was required under a previous policy.
VERBATIM QUESTION: Why might a laboratory not be posted on the lab notification list?
VERBATIM ANSWER: Yeah, we can look at that. And there is a difference between having submitted an EUA request and having notified, and so we can look into whether that's part of the issue. An applicant doesn't get listed on the notification list based on an EUA request being submitted. It's only if a notification was submitted earlier in the emergency, when we were accepting notifications through the previous policy.
SPEAKER QUESTION: Debs Payne
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: lab notification list, EUA process, FDA policy changes
REVIEW FLAG: False

QA Block 10-4
CLARIFIED QUESTION: Does an applicant get listed on the lab notification list based on submitting an EUA request, or is it only if a notification was submitted earlier during the emergency?
CLARIFIED ANSWER: FDA confirms that applicants are listed on the lab notification list only if a notification was submitted earlier during the emergency under the previous policy, not for submitting an EUA request.
VERBATIM QUESTION: Does an applicant get listed on the lab notification list based on submitting an EUA request, or is it only if a notification was submitted earlier during the emergency?
VERBATIM ANSWER: An applicant doesn't get listed on the notification list based on an EUA request being submitted. It's only if a notification was submitted earlier in the emergency, when we were accepting notifications through the previous policy.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA process, Lab notification list, Notification policy
REVIEW FLAG: False

QA Block 10-5
CLARIFIED QUESTION: What should be included in an email to the FDA COVID-19 email box when seeking clarification on lab notification status?
CLARIFIED ANSWER: Send an email to the FDA COVID-19 email box and request that it be submitted to Kris, Toby, and Tim for clarification on lab notification status.
VERBATIM QUESTION: What should be included in an email to the FDA COVID-19 email box when seeking clarification on lab notification status?
VERBATIM ANSWER: Go ahead and send an email to the COVID email box, and ask this be submitted to Kris, Toby, and Tim.
SPEAKER QUESTION: Debs Payne
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: lab notification status, FDA email communication
REVIEW FLAG: False

QA Block 10-6
CLARIFIED QUESTION: What changes in the FDA's processes might affect whether a lab is posted on the notification list?
CLARIFIED ANSWER: FDA noted that some processes affecting lab postings on the notification list have changed over time.
VERBATIM QUESTION: What changes in the FDA's processes might affect whether a lab is posted on the notification list?
VERBATIM ANSWER: And Toby may be able to expand why or why not something, in general, may not be posted. I think some of our processes have changed over time.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA process changes, Lab notification list
REVIEW FLAG: False

QA Block 10-7
CLARIFIED QUESTION: How can a laboratory determine if it needs to re-notify the FDA due to changes in policies for lab notification?
CLARIFIED ANSWER: An applicant does not get listed on the lab notification list solely by submitting an EUA request. They would need to have submitted a notification under the earlier emergency policy when those were being accepted.
VERBATIM QUESTION: How can a laboratory determine if it needs to re-notify the FDA due to changes in policies for lab notification?
VERBATIM ANSWER: There is a difference between having submitted an EUA request and having notified, and so we can look into whether that's part of the issue. An applicant doesn't get listed on the notification list based on an EUA request being submitted. It's only if a notification was submitted earlier in the emergency, when we were accepting notifications through the previous policy.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: lab notification policies, FDA lab listing, EUA vs. notification
REVIEW FLAG: False

QA Block 10-8
CLARIFIED QUESTION: What should a laboratory do if their assigned EUA reviewer is unresponsive?
CLARIFIED ANSWER: FDA advises contacting them and their team for follow-up when a reviewer is unresponsive; in this case, Toby from FDA will address it.
VERBATIM QUESTION: What should a laboratory do if their assigned EUA reviewer is unresponsive?
VERBATIM ANSWER: OK, well, Toby's on top of it. Go ahead, Toby.
SPEAKER QUESTION: Debs Payne
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA reviewer unresponsiveness, EUA communication
REVIEW FLAG: False


#### 11. Clarification on FDA Guidance for EUA IVD Distribution

QA Block 11-1
CLARIFIED QUESTION: Does the FDA intend to require the authorized distributors under the EUAs to stop distribution of product already in their control and out of the manufacturer's control after the EUA termination date?
CLARIFIED ANSWER: The FDA recommends checking the upcoming final guidances, which are expected to provide more clarity on this matter. Questions after their release can be submitted, and relevant webinars will also be available.
VERBATIM QUESTION: Does the FDA intend to require the authorized distributors under the EUAs to stop distribution of product already in their control and out of the manufacturer's control after the EUA termination date?
VERBATIM ANSWER: Yeah, a little bit, but I think I understand the gist of your question. And the main answer really is to keep an eye out for the final guidances. We do expect them to post very soon based on the public notice that OMB has completed their review. So keep an eye out for those, and I think that they will provide more of the clarity that you're looking for. And then if you still have questions after the final guidances are posted, please send those in, and also keep an eye out for the webinars that will be focused specifically on those final guidances.
SPEAKER QUESTION: Eileen McCafferty
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA termination, distribution of IVDs, FDA guidances
REVIEW FLAG: False

QA Block 11-3
CLARIFIED QUESTION: Will the FDA host webinars to address specific questions about the final transition guidance?
CLARIFIED ANSWER: The FDA plans to host webinars focused on addressing specific questions about the final transition guidances.
VERBATIM QUESTION: Will the FDA host webinars to address specific questions about the final transition guidance?
VERBATIM ANSWER: And then if you still have questions after the final guidances are posted, please send those in, and also keep an eye out for the webinars that will be focused specifically on those final guidances.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: webinars, transition guidance, IVDs
REVIEW FLAG: False

QA Block 11-4
CLARIFIED QUESTION: What additional resources will the FDA provide to clarify the final guidance on the discontinuation of IVD distribution after the EUA termination date?
CLARIFIED ANSWER: The FDA will soon post the final guidances, which should provide clarity. Stakeholders are also encouraged to send follow-up questions after the guidances are posted and watch for webinars dedicated to these final guidances.
VERBATIM QUESTION: What additional resources will the FDA provide to clarify the final guidance on the discontinuation of IVD distribution after the EUA termination date?
VERBATIM ANSWER: We do expect them to post very soon based on the public notice that OMB has completed their review. So keep an eye out for those, and I think that they will provide more of the clarity that you're looking for. And then if you still have questions after the final guidances are posted, please send those in, and also keep an eye out for the webinars that will be focused specifically on those final guidances.
SPEAKER QUESTION: Eileen McCafferty
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: IVD distribution post-EUA, Final guidances, FDA webinars
REVIEW FLAG: False


#### 12. Breath Test EUA Template Not Being Published

QA Block 12-1
CLARIFIED QUESTION: Will there be a published EUA template for breath tests?
CLARIFIED ANSWER: The FDA will not publish a breath test EUA template due to the limited number of such tests. Developers can submit a pre-EUA to receive standard recommendations for breath test validations from the FDA.
VERBATIM QUESTION: Will there be a published EUA template for breath tests?
VERBATIM ANSWER: No, there will not be a breath test template published. We're just not seeing a ton of those to justify the process that we have to go to clear a template and post it. But you can send a pre- EUA in requesting our standard recommendations for a breath test. That will go to the breath test team, and they will respond with their current recommendations for breath test validations.
SPEAKER QUESTION: Alexandra Hubenko
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA templates, breath tests, FDA recommendations
REVIEW FLAG: False

QA Block 12-2
CLARIFIED QUESTION: What is the process for submitting a pre-EUA request for breath tests?
CLARIFIED ANSWER: Submit a pre-EUA request to the FDA's breath test team, who will provide their standard recommendations for breath test validation.
VERBATIM QUESTION: What is the process for submitting a pre-EUA request for breath tests?
VERBATIM ANSWER: You can send a pre-EUA in requesting our standard recommendations for a breath test. That will go to the breath test team, and they will respond with their current recommendations for breath test validations.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUA process, breath test validation
REVIEW FLAG: False

QA Block 12-3
CLARIFIED QUESTION: What recommendations does the FDA currently have for validating breath tests?
CLARIFIED ANSWER: FDA recommends submitting a pre-EUA to request the agency's standard recommendations for breath test validation, which will be provided by their breath test team.
VERBATIM QUESTION: What recommendations does the FDA currently have for validating breath tests?
VERBATIM ANSWER: You can send a pre-EUA in requesting our standard recommendations for a breath test. That will go to the breath test team, and they will respond with their current recommendations for breath test validations.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA breath test validation, pre-EUA submissions, breath test recommendations
REVIEW FLAG: False


#### 13. COVID Transition Guidances and EUA Termination Plans

QA Block 13-1
CLARIFIED QUESTION: Are there any plans at this time for COVID-19 and mpox EUAs to go away?
CLARIFIED ANSWER: FDA is finalizing COVID-19 transition guidances, but these do not initiate the 180-day notice period. No timeline exists currently for ending COVID-19 or mpox EUAs, and the Secretary of HHS would announce such decisions with sufficient notice.
VERBATIM QUESTION: Are there any plans at this time for COVID-19 and mpox EUAs to go away?
VERBATIM ANSWER: Yeah, sure. So again, we are working on getting the final COVID transition guidances posted. That should be done very soon. That said, the guidances do not trigger that 180 days. We do not have any timeline on that at the moment. That would be an announcement, I believe, from the Secretary of HHS giving that advanced notice of terminating the 564 declaration.
SPEAKER QUESTION: Stacey Moltchanoff
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: COVID-19 EUAs, mpox EUAs, HHS announcements
REVIEW FLAG: False

QA Block 13-2
CLARIFIED QUESTION: If the EUAs are to end, how would that be communicated?
CLARIFIED ANSWER: The end of EUAs would be communicated via an announcement from the Secretary of HHS providing advanced notice of the termination of the 564 declaration.
VERBATIM QUESTION: If the EUAs are to end, how would that be communicated?
VERBATIM ANSWER: That would be an announcement, I believe, from the Secretary of HHS giving that advanced notice of terminating the 564 declaration.
SPEAKER QUESTION: Stacey Moltchanoff
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA termination, communication, HHS announcement
REVIEW FLAG: False


#### 14. FDA Preferences for Flu Assay Differentiation

QA Block 14-1
CLARIFIED QUESTION: What is the FDA's preference between a COVID and flu-A-only assay versus a COVID and pan flu assay as we move forward into 510(k)s?
CLARIFIED ANSWER: The FDA is open to both types of assays and encourages developers to present their technologies and address risks such as not differentiating flu A and B.
VERBATIM QUESTION: What is the FDA's preference between a COVID and flu-A-only assay versus a COVID and pan flu assay as we move forward into 510(k)s?
VERBATIM ANSWER: So there are some technologies that just don't have enough channels to report all of the, say, flu A and B, and maybe only can report one result and not two. And so we are, again, open to alterations in the pathways, to authorizations of tests that are of public health importance. So we would recommend that you come in with your technology and explain how you would control any potential risks from not differentiating flu A and B and discuss that option with us.
SPEAKER QUESTION: Ling Koh
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID and flu assays, flu A and pan flu, 510(k) preferences
REVIEW FLAG: False

QA Block 14-2
CLARIFIED QUESTION: Could you comment on the January Town Hall response on pan flu assays and the openness indicated in it?
CLARIFIED ANSWER: The FDA is open to authorizations for tests like pan flu assays if public health importance is demonstrated and risks of not differentiating flu A and B are controlled.
VERBATIM QUESTION: Could you comment on the January Town Hall response on pan flu assays and the openness indicated in it?
VERBATIM ANSWER: So there are some technologies that just don't have enough channels to report all of the, say, flu A and B, and maybe only can report one result and not two. And so we are, again, open to alterations in the pathways, to authorizations of tests that are of public health importance. So we would recommend that you come in with your technology and explain how you would control any potential risks from not differentiating flu A and B and discuss that option with us.
SPEAKER QUESTION: Ling Koh
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pan flu assays, public health test authorizations, differentiating flu A and B
REVIEW FLAG: False

QA Block 14-3
CLARIFIED QUESTION: What are the considerations for authorizing COVID-19 diagnostic tests that cannot differentiate between flu A and flu B?
CLARIFIED ANSWER: FDA acknowledges that some technologies cannot differentiate between flu A and flu B due to technical limitations. They are open to authorizing such tests if risks are managed appropriately and recommend discussing these risks and controls during submission.
VERBATIM QUESTION: What are the considerations for authorizing COVID-19 diagnostic tests that cannot differentiate between flu A and flu B?
VERBATIM ANSWER: So there are some technologies that just don't have enough channels to report all of the, say, flu A and B, and maybe only can report one result and not two. And so we are, again, open to alterations in the pathways, to authorizations of tests that are of public health importance. So we would recommend that you come in with your technology and explain how you would control any potential risks from not differentiating flu A and B and discuss that option with us.
SPEAKER QUESTION: Ling Koh
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19 diagnostic tests, Flu A and B differentiation, FDA authorization process
REVIEW FLAG: False

QA Block 14-4
CLARIFIED QUESTION: How should developers present their technology to address the risks of not differentiating flu A and flu B?
CLARIFIED ANSWER: FDA recommends that developers present their technology and explain how potential risks from not differentiating flu A and B are controlled, discussing these options with them.
VERBATIM QUESTION: How should developers present their technology to address the risks of not differentiating flu A and flu B?
VERBATIM ANSWER: So there are some technologies that just don't have enough channels to report all of the, say, flu A and B, and maybe only can report one result and not two. And so we are, again, open to alterations in the pathways, to authorizations of tests that are of public health importance. So we would recommend that you come in with your technology and explain how you would control any potential risks from not differentiating flu A and B and discuss that option with us.
SPEAKER QUESTION: Ling Koh
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Flu A/Flu B differentiation, Diagnostic assay risks, FDA recommendations
REVIEW FLAG: False

QA Block 14-5
CLARIFIED QUESTION: What kind of expert opinion or evidence should developers provide to support differentiation between flu A and flu B if their assays have that capability?
CLARIFIED ANSWER: FDA emphasized the importance of expert opinion, including input from physicians within or outside the organization, to address the risks in differentiating flu A and B.
VERBATIM QUESTION: What kind of expert opinion or evidence should developers provide to support differentiation between flu A and flu B if their assays have that capability?
VERBATIM ANSWER: The only thing I'd like to highlight is just the risks. Come in, let us know if you've got expert opinion in differentiating flu A and B. We'd love to hear that opinion. Certainly, physicians that are in your organization, outside your organization, so that's something that we'd like to know more about.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: expert opinion, flu A and B differentiation, risks
REVIEW FLAG: False

QA Block 14-6
CLARIFIED QUESTION: Do advancements in technology limitations impact FDA's openness to authorizing assays that do not distinguish between flu A and B?
CLARIFIED ANSWER: The FDA is open to authorizing tests that do not distinguish between flu A and B if technological limitations prevent differentiation, provided that developers outline risk control strategies.
VERBATIM QUESTION: Do advancements in technology limitations impact FDA's openness to authorizing assays that do not distinguish between flu A and B?
VERBATIM ANSWER: So there are some technologies that just don't have enough channels to report all of the, say, flu A and B, and maybe only can report one result and not two. And so we are, again, open to alterations in the pathways, to authorizations of tests that are of public health importance. So we would recommend that you come in with your technology and explain how you would control any potential risks from not differentiating flu A and B and discuss that option with us.
SPEAKER QUESTION: Ling Koh
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Technology limitations, Authorization of tests, Flu A and B differentiation
REVIEW FLAG: False

QA Block 14-7
CLARIFIED QUESTION: How can test developers demonstrate the public health importance of their assays when seeking FDA authorization?
CLARIFIED ANSWER: FDA recommends test developers present their technology alongside an explanation of risk controls for not differentiating certain results to demonstrate public health importance and seek authorization.
VERBATIM QUESTION: How can test developers demonstrate the public health importance of their assays when seeking FDA authorization?
VERBATIM ANSWER: So there are some technologies that just don't have enough channels to report all of the, say, flu A and B, and maybe only can report one result and not two. And so we are, again, open to alterations in the pathways, to authorizations of tests that are of public health importance. So we would recommend that you come in with your technology and explain how you would control any potential risks from not differentiating flu A and B and discuss that option with us.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: test authorization, public health importance, risk controls
REVIEW FLAG: False


#### 15. EUA Transition and Regulatory Pathway Clarifications

QA Block 15-1
CLARIFIED QUESTION: Will the FDA still approve new EUA submissions after the final transition plan comes out, or will developers need to switch to the 510(k) pathway or another process?
CLARIFIED ANSWER: FDA is still reviewing EUA requests for submissions aligning with public health priorities and will provide a response for pending requests. However, developers are recommended to move towards traditional marketing submissions.
VERBATIM QUESTION: Will the FDA still approve new EUA submissions after the final transition plan comes out, or will developers need to switch to the 510(k) pathway or another process?
VERBATIM ANSWER: So the guidance document does not terminate the 564 declaration, as we mentioned. So as we've talked about, we are recommending that developers move toward traditional marketing submissions. We are continuing to review EUA requests for a small number of submissions that meet our current priorities based on the public health needs. But we are, the 564 is still open, and the guidance document does not change that. And so we'll continue to work through the priority submissions that we are reviewing. And every developer with an EUA request that is in-house and still open will receive a response either that we are declining to review or declining to issue, or that we are authorizing it, depending on how everything goes. So you will get a response. We just can't say what that response will be at this time.
SPEAKER QUESTION: Homer Wu
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA submissions, Transition to 510(k)
REVIEW FLAG: False

QA Block 15-2
CLARIFIED QUESTION: In the final transition for existing EUAs, will developers have to switch to the de novo pathway if their test does not already have a predicate device?
CLARIFIED ANSWER: FDA confirms that if a device does not have an appropriate predicate, developers will need to use the de novo pathway.
VERBATIM QUESTION: In the final transition for existing EUAs, will developers have to switch to the de novo pathway if their test does not already have a predicate device?
VERBATIM ANSWER: So we do have-- there are de novos granted for a couple of device types. If there is not an appropriate predicate for your particular device, then yes, it would need to go through de novo.
SPEAKER QUESTION: Homer Wu
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: final transition for EUAs, de novo pathway, predicate device
REVIEW FLAG: False

QA Block 15-3
CLARIFIED QUESTION: For antigen tests, since there is no de novo pathway for at-home OTC use, is the only available option the de novo pathway?
CLARIFIED ANSWER: FDA confirms that for at-home OTC antigen tests, there are no de novo pathways available, making it the only option.
VERBATIM QUESTION: For antigen tests, since there is no de novo pathway for at-home OTC use, is the only available option the de novo pathway?
VERBATIM ANSWER: That's correct.
SPEAKER QUESTION: Homer Wu
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: at-home OTC antigen tests, de novo pathway, EUA transition
REVIEW FLAG: False


#### 16. Transition Guidance Unnecessary for Mpox Testing Authorization

QA Block 16-1
CLARIFIED QUESTION: Will there be any plans to have a COVID transition draft guidance for mpox?
CLARIFIED ANSWER: FDA does not plan to issue a transition draft guidance for mpox as the situation is very different from COVID-19. Mpox cases are very low, making clinical studies challenging; EUA authorities remain sufficient for ensuring test availability.
VERBATIM QUESTION: Will there be any plans to have a COVID transition draft guidance for mpox?
VERBATIM ANSWER: I'll take this. So mpox is a whole lot different than COVID-19. There continue to be, in the last few days, 30,000 new cases known in the US, and may underestimate it. And we anticipate that COVID-19 will be with us probably for much longer than we hope. With mpox, there are very few cases. The last time I checked, there was 1.7 cases a day in the United States. That's probably a week-old data. And it would be super, super challenging to try to do a prospective clinical study anywhere in the world right now for mpox in order to transition EUAs to full authorization in an acceptable manner. So this is the perfect situation for the EUA authorities, where we can keep the 564 declaration in place, if we wish, in order that there is still access to testing for mpox. And we do believe that there is a continued need for mpox, and we want to have tests continue to be available. And in fact, there still are some priority categories for EUAs for mpox, and that doesn't include-- the primary category now for mpox is really a multi-analyte point-of-care mpox test that includes other commonly-seen and potentially overlapping with symptoms and presentation with mpox, STDs. But it is fairly focused and limited. But the US government is interested in continuing to have a test availability to keep pressure on keeping any sort of potential resurgence mitigated and addressed. So there isn't really a need for transition guidance, and we didn't do it for others that are still-- 564 that are open. That includes things like Zika and Ebola. And in fact, this year, we've already used the Ebola authorities to make sure that our nation-- and last year-- that our nation has appropriate countermeasures, IVD countermeasures for Ebola because of the outbreak that, fortunately, never reached our shores, but needed to be dealt with exterior to the US. But we needed to be prepared in the US for anything that might happen here.
SPEAKER QUESTION: Stacey Moltchanoff
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: mpox transition guidance, EUA authorities, test availability
REVIEW FLAG: False

### removed qa blocks
QA Block 2-4
CLARIFIED QUESTION: What steps should be taken to use a comparator cleared more than five years ago for flu testing?
CLARIFIED ANSWER: FDA may accept comparators cleared over five years ago if evidence shows test performance remains consistent with current circulating flu strains, such as through in silico analysis of primers and probes.
VERBATIM QUESTION: What steps should be taken to use a comparator cleared more than five years ago for flu testing?
VERBATIM ANSWER: However, we may consider a comparator that has been cleared previous to that time frame if you can demonstrate that the test performance is expected to remain unchanged with currently circulating flu strains; for example, providing an in silico analysis of the primers and probes, including contemporary strains.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: FDA comparator guidelines, Flu testing, Comparator test clearance timeline
REVIEW FLAG: False

QA Block 2-5
CLARIFIED QUESTION: What is the recommended comparator for other analytes in a respiratory panel?
CLARIFIED ANSWER: FDA recommends using a high-sensitivity FDA-cleared test, cleared within the past 5 to 10 years, as the comparator for other analytes in a respiratory panel.
VERBATIM QUESTION: What is the recommended comparator for other analytes in a respiratory panel?
VERBATIM ANSWER: We similarly recommend using a high-sensitivity FDA cleared test, cleared within the past 5 to 10 years for other analytes in your respiratory panel. And again, bring us a Q-Sub and make these proposals to us in writing, and we can reply to you very quickly.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: Comparator methods, Respiratory panel analytes, FDA recommendations
REVIEW FLAG: False

QA Block 2-9
CLARIFIED QUESTION: What are the adjusted recommendations for developers regarding flu B prospective clinical study targets to support CLIA waiver or over-the-counter IVD indications?
CLARIFIED ANSWER: FDA has adjusted its recommendations for flu B validation to require a target of at least 30 influenza-B-positive subjects in a prospective clinical study for CLIA waiver or OTC IVD indications, reduced from the previous 120-subject requirement.
VERBATIM QUESTION: What are the adjusted recommendations for developers regarding flu B prospective clinical study targets to support CLIA waiver or over-the-counter IVD indications?
VERBATIM ANSWER: Due to the low levels of flu B in the past few seasons, we are adjusting our general recommendations for developers to target at least 30 influenza-B-positive subjects in a prospective clinical study to support CLIA waiver or over-the-counter IVD indications. This differs from feedback developers may have previously received, such as in Q-Submissions. These previous recommendations for testing included a target of 120 subjects positive by the comparator method for flu B to support CLIA waiver and OTC IVD indications. Again, we encourage developers to continue engaging with us on this topic.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: flu B validation, CLIA waiver, IVD indications
REVIEW FLAG: False

QA Block 4-4
CLARIFIED QUESTION: How should risks associated with hazardous materials in at-home test devices be communicated in labeling?
CLARIFIED ANSWER: FDA advises including information in assay labeling to inform users about risks associated with the device, along with guidance on personal protective equipment usage.
VERBATIM QUESTION: How should risks associated with hazardous materials in at-home test devices be communicated in labeling?
VERBATIM ANSWER: We recommend that your proposed assay labeling inform users of the risks associated with the use of your device as well as any recommendations for personal protective equipment.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: hazardous materials, at-home test labeling, risk communication
REVIEW FLAG: False

QA Block 8-1
CLARIFIED QUESTION: Is it acceptable for clinical studies of an at-home antigen test to collect the comparator method test swab sample prior to the candidate test swab sample?
CLARIFIED ANSWER: Yes, it is acceptable as long as standard of care procedures, including IRB recommendations, are followed. Pausing between collections, such as a 15-minute interval, is also reasonable. This can be addressed through the pre-EUA or Q-Sub process if needed.
VERBATIM QUESTION: Is it acceptable for clinical studies of an at-home antigen test to collect the comparator method test swab sample prior to the candidate test swab sample?
VERBATIM ANSWER: Yes. You do need to follow standard of care procedures per IRB recommendations, when appropriate. That can be a molecular rather than, necessarily, an antigen test. But obviously, it takes longer to get that molecular result back than an on-site antigen test. You can pause between collections, particularly between the molecular comparator collection and the candidate test collection, to allow what we call a washout period. Or we've seen in developers, sponsors of studies wait 15 minutes in between collections, and to date I'm not aware of any challenges that put any of the comparisons at a disadvantage. And you can also address this, if you wish, through, if it's an EUA submission, through the pre-EUA process or a Q-Sub if it's for a full authorization process.
SPEAKER QUESTION: Mary V
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: at-home antigen test studies, sample collection order, FDA submission processes
REVIEW FLAG: False

QA Block 9-3
CLARIFIED QUESTION: What is considered a "manufacturing role" if a clinical laboratory wishes to act as a sponsor for an FDA submission?
CLARIFIED ANSWER: In this scenario, a clinical laboratory would take on the role of manufacturer if they assume responsibility for the production of the test themselves.
VERBATIM QUESTION: What is considered a "manufacturing role" if a clinical laboratory wishes to act as a sponsor for an FDA submission?
VERBATIM ANSWER: Your specific situation has some inherent challenges, because I take it that it would still be a manufactured test. But you're not the manufacturer, unless you take on the manufacturing role for your own situation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: manufacturing role definition, clinical labs as sponsors, FDA submissions
REVIEW FLAG: False

QA Block 11-2
CLARIFIED QUESTION: When will the FDA release the final guidance documents addressing the transition of IVDs post-EUA?
CLARIFIED ANSWER: The FDA expects to release the final guidance documents very soon as the OMB has completed its review. Additional clarity can be sought in upcoming webinars or through follow-up questions after the release.
VERBATIM QUESTION: When will the FDA release the final guidance documents addressing the transition of IVDs post-EUA?
VERBATIM ANSWER: We do expect them to post very soon based on the public notice that OMB has completed their review. So keep an eye out for those, and I think that they will provide more of the clarity that you're looking for. And then if you still have questions after the final guidances are posted, please send those in, and also keep an eye out for the webinars that will be focused specifically on those final guidances.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: IVD transition, EUA final guidance release, FDA processes
REVIEW FLAG: False


### extract log
#### extract log header
datetime: 2025-01-05 17:25:50 UTC-08:00 America/Los_Angeles
source file prep: primary.llm.add_transcript_section_delimiters for non-FDA speakers
ROUND 1 NAME: Explicit Questions Extraction
- prompt: FCALL_SYSTEM_PROMPT_QA_QONLY_EXPLICIT_1D
- tools: tools_qa_qonly_explicit_1
- provider: openai
- model: gpt-4o-2024-11-20

#### Section 1 of 16
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 1-1: What are the next steps for transitioning from EUA tests to fully authorized tests under traditional marketing submissions?
QI 1-2: How can developers leverage EUA data to reduce validation requirements when transitioning to fully authorized tests?
QI 1-3: What is the process for obtaining FDA validation recommendations for a specific device type?
QI 1-4: What COVID-19 and mpox EUA review priorities is the FDA focusing on at this stage?
QI 1-5: When will the final guidance on the COVID-19 transition plan be released?
QI 1-6: Will there be opportunities for FDA-hosted webinars focused on specific IVD topics after the end of regular town halls?
QI 1-7: How flexible is the FDA in adapting its recommendations for specific developer challenges during the transition process?
QI 1-8: What is the procedure for proposing modifications or alternatives to FDA recommendations through the pre-EUA or Q-Sub processes?
QI 1-9: What is the FDA's current position on developing and authorizing mpox screening tests?
QI 1-10: Are US government-sponsored studies on mpox screening tests influencing FDA recommendations or approval processes?

#### Section 2 of 16
##### Explicit Questions Extraction
QE 2-1: What are the appropriate COVID-19 comparator methods to support a de novo or 510k premarket submission?
QE 2-2: What comparator method do you recommend for flu when supporting a multi-analyte respiratory panel?
QE 2-3: Can a comparator cleared over five years ago be used if the test performance remains unchanged with currently circulating flu strains?
QE 2-4: What steps should be taken to use a comparator cleared more than five years ago for flu testing?
QE 2-5: What is the recommended comparator for other analytes in a respiratory panel?
QE 2-6: What information should be included in a Pre-Sub or Q-Sub regarding specific potential comparators and study design?
QE 2-7: What are your recommendations for flu B validation given its low prevalence in the U.S.?
QE 2-8: What were the conditions for authorization for the Lucira COVID-19 and flu home test related to flu validation?
QE 2-9: What are the adjusted recommendations for developers regarding flu B prospective clinical study targets to support CLIA waiver or over-the-counter IVD indications?

##### Implicit Questions Extraction
QI 2-1: What is the relationship between the expiry of the 319 public health emergency and the continuation of the 564 EUA declaration?
QI 2-2: How will manufacturers of EUA-authorized COVID-19 tests transition to normal operations once the 564 declaration ends?
QI 2-3: Will the FDA allow continued distribution of tests under EUA while their traditional marketing submissions are being reviewed?
QI 2-4: What is the timeline for the publication of the final transition plan guidance?
QI 2-5: What actions should test developers take if they are currently planning their COVID-19 test submissions post-transition?
QI 2-6: What are the FDA's considerations for using a comparator cleared more than five years ago for flu testing?
QI 2-7: What is the updated target for influenza B-positive subjects in a prospective clinical study for CLIA waiver or OTC indications, and how does it differ from previous recommendations?

#### Section 3 of 16
##### Explicit Questions Extraction
QE 3-1: Can an over-the-counter COVID-19 antigen test be submitted through the 510(k) pathway now using Quidel's Sofia 2 test as the predicate device?

##### Implicit Questions Extraction
QI 3-1: What is the process for receiving FDA feedback for questions that are too detailed for the town hall?
QI 3-2: How should test developers follow up on unanswered questions sent to the FDA for the town hall?
QI 3-3: What happens to follow-up questions arising from pre-EUA or pre-submission feedback if they are not addressed during a town hall?
QI 3-4: What steps should a developer take if they do not receive a timely written response from the FDA after submitting a question?
QI 3-5: What is the de novo process for granting marketing authorization for over-the-counter COVID-19 antigen tests?
QI 3-6: Are there plans for the FDA to establish specific regulations and special controls for at-home over-the-counter COVID-19 antigen tests similar to those for point-of-care tests?

#### Section 4 of 16
##### Explicit Questions Extraction
QE 4-1: Is it acceptable to include guanidine hydrochloride in an at-home SARS-CoV-2 test?

##### Implicit Questions Extraction
QI 4-1: What safety features should be included to mitigate the risk of patient exposure to hazardous materials in at-home test devices?
QI 4-2: What specific design details should be submitted to the FDA for the assessment of hazardous materials in test components?
QI 4-3: How should risks associated with hazardous materials in at-home test devices be communicated in labeling?
QI 4-4: What recommendations for personal protective equipment should be included in the labeling of at-home test devices involving hazardous materials?
QI 4-5: What happens during the FDA's independent risk assessment of an at-home test device's proposed safety mitigations?

#### Section 5 of 16
##### Explicit Questions Extraction
QE 5-1: Will the FDA update the code QMN in the product classification database given the encouragement for manufacturers to avoid the EUA route?

##### Implicit Questions Extraction
QI 5-1: How will newly approved COVID-19 tests be categorized if traditional premarket authorization pathways are used?
QI 5-2: Where can test developers find information on procodes for COVID-19 tests approved under the 510(k) or de novo pathways?
QI 5-3: Will product codes be created for COVID-19 tests that transition from EUA to regular market authorization?

#### Section 6 of 16
##### Explicit Questions Extraction
QE 6-1: Can the FDA comment on the current thinking regarding single-target COVID tests for emergency use authorization now that there is a large database of genomic information available for manufacturers to utilize in the design of IVD tests?
QE 6-2: Would it be acceptable to use a single-target COVID test approach for future premarket submissions?

##### Implicit Questions Extraction
QI 6-1: What are the potential risks to public health when using single-target molecular COVID-19 tests as new variants emerge?
QI 6-2: What additional labeling requirements might be necessary for single-target molecular tests to mitigate risks associated with mutations?
QI 6-3: Why do multi-target SARS-CoV-2 tests have a lower probability of being affected by new mutations compared to single-target tests?
QI 6-4: Are there publicly available FDA resources regarding changes in test performance as new SARS-CoV-2 variants emerge?
QI 6-5: Can labeling mitigations for single-target tests help ensure adequate performance against emerging variants?

#### Section 7 of 16
##### Explicit Questions Extraction
QE 7-1: What recommendations do you have if a sponsor does not have retrospective samples to demonstrate flu B performance due to low prevalence?

##### Implicit Questions Extraction
QI 7-1: How can flu B samples be collected from the Southern hemisphere if prevalence is higher there?
QI 7-2: What alternate methods to demonstrate flu B performance are acceptable under an EUA for a combined flu and COVID test?
QI 7-3: How can a developer turn off or mask a flu B signal in an antigen test to address validation challenges?
QI 7-4: What options are available for electronically masking flu B signals in molecular tests?
QI 7-5: What should be included in a proposal to validate flu B performance when samples are limited?

#### Section 8 of 16
##### Explicit Questions Extraction
QE 8-1: Is it acceptable for clinical studies of an at-home antigen test to collect the comparator method test swab sample prior to the candidate test swab sample?
QE 8-2: If the standard of care at a clinical site is to first test with an FDA EUA at-home antigen test, then collect a comparator method test swab, and then collect the candidate test's sample, is this order of collection acceptable?

##### Implicit Questions Extraction
QI 8-1: What is the recommended duration for a washout period between the molecular comparator collection and the candidate test collection?
QI 8-2: Are there differences in regulatory submission processes between EUA submissions and full authorization processes in terms of sample collection protocols?
QI 8-3: How have concerns about training users to self-collect nasal swab samples evolved since the beginning of the pandemic?
QI 8-4: Does the FDA still consider the involvement of health care professionals in sample collection as a potential source of bias in clinical studies?
QI 8-5: To what extent does the widespread distribution of home tests impact current study designs or evaluations for COVID-19 diagnostics?
QI 8-6: What are the implications of reduced availability of unbiased candidate test subjects for home respiratory testing studies?

#### Section 9 of 16
##### Explicit Questions Extraction
QE 9-1: Does the FDA plan to issue specific guidance directed towards clinical laboratories pursuing a 510k or a path to clearance for their institution, specifically for cases where the SARS-CoV-2 test manufacturer is not pursuing clearance?
QE 9-2: Can a clinical laboratory act as the sponsor or the manufacturer in a Pre-Submission process while working with the original manufacturer as a supplier?

##### Implicit Questions Extraction
QI 9-1: What is considered a "manufacturing role" if a clinical laboratory wishes to act as a sponsor for an FDA submission?
QI 9-2: What are the inherent challenges the FDA foresees in a scenario where a test is developed by a lab but the original manufacturer acts as a supplier?
QI 9-3: What is the significance of submitting plans through a Pre-Submission or Q-Submission for unique scenarios like this?
QI 9-4: What level of detail should be included when presenting a unique case in a Q-Submission or Pre-Submission to the FDA?
QI 9-5: How does the FDA use the formal record created through Q-Submission or Pre-Submission responses in future interactions?
QI 9-6: What guidance is available for navigating the FDA Q-Submission process?

#### Section 10 of 16
##### Explicit Questions Extraction
QE 10-1: Who do I need to contact to get the Promega Clinical Lab (PCL) listed in the lab notification list on the FDA website?
QE 10-2: Is my reviewer still assigned to me?
QE 10-3: Why might a laboratory not be posted on the lab notification list?
QE 10-4: Does an applicant get listed on the lab notification list based on submitting an EUA request, or is it only if a notification was submitted earlier during the emergency?

##### Implicit Questions Extraction
QI 10-1: What should be included in an email to the FDA COVID-19 email box when seeking clarification on lab notification status?
QI 10-2: What changes in the FDA's processes might affect whether a lab is posted on the notification list?
QI 10-3: How can a laboratory determine if it needs to re-notify the FDA due to changes in policies for lab notification?
QI 10-4: What should a laboratory do if their assigned EUA reviewer is unresponsive?

#### Section 11 of 16
##### Explicit Questions Extraction
QE 11-1: Does the FDA intend to require the authorized distributors under the EUAs to stop distribution of product already in their control and out of the manufacturer's control after the EUA termination date?

##### Implicit Questions Extraction
QI 11-1: When will the FDA release the final guidance documents addressing the transition of IVDs post-EUA?
QI 11-2: Will the FDA host webinars to address specific questions about the final transition guidance?
QI 11-3: What additional resources will the FDA provide to clarify the final guidance on the discontinuation of IVD distribution after the EUA termination date?

#### Section 12 of 16
##### Explicit Questions Extraction
QE 12-1: Will there be a published EUA template for breath tests?

##### Implicit Questions Extraction
QI 12-1: What is the process for submitting a pre-EUA request for breath tests?
QI 12-2: What recommendations does the FDA currently have for validating breath tests?

#### Section 13 of 16
##### Explicit Questions Extraction
QE 13-1: Are there any plans at this time for COVID-19 and mpox EUAs to go away?
QE 13-2: If the EUAs are to end, how would that be communicated?

##### Implicit Questions Extraction

#### Section 14 of 16
##### Explicit Questions Extraction
QE 14-1: What is the FDA's preference between a COVID and flu-A-only assay versus a COVID and pan flu assay as we move forward into 510(k)s?
QE 14-2: Could you comment on the January Town Hall response on pan flu assays and the openness indicated in it?

##### Implicit Questions Extraction
QI 14-1: What are the considerations for authorizing COVID-19 diagnostic tests that cannot differentiate between flu A and flu B?
QI 14-2: How should developers present their technology to address the risks of not differentiating flu A and flu B?
QI 14-3: What kind of expert opinion or evidence should developers provide to support differentiation between flu A and flu B if their assays have that capability?
QI 14-4: Do advancements in technology limitations impact FDA's openness to authorizing assays that do not distinguish between flu A and B?
QI 14-5: How can test developers demonstrate the public health importance of their assays when seeking FDA authorization?

#### Section 15 of 16
##### Explicit Questions Extraction
QE 15-1: Will the FDA still approve new EUA submissions after the final transition plan comes out, or will developers need to switch to the 510(k) pathway or another process?
QE 15-2: In the final transition for existing EUAs, will developers have to switch to the de novo pathway if their test does not already have a predicate device?
QE 15-3: For antigen tests, since there is no de novo pathway for at-home OTC use, is the only available option the de novo pathway?

##### Implicit Questions Extraction

#### Section 16 of 16
##### Explicit Questions Extraction
QE 16-1: Will there be any plans to have a COVID transition draft guidance for mpox?

##### Implicit Questions Extraction
